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Figure 1 Schematic representation of hematopoiesis. The pluripotent stem cells give rise to 
committed lymphoid and myeloid progenitor cells. Commitment, proliferation and further 
development to fully differentiated cells occurs under the control of HGFs/cytokines. Major (but not 
all) HGFs involved in hematopoiesis are indicated. 
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1.1 Hematopoiesis 
All blood cells originate from the hematopoietic stem cells, that are capable of both 
self renewal and differentiation towards the lineage committed progenitor cells 
(figure 1). The primary site of blood cell formation or hematopoiesis is the bone 
Illarrow. The bone rnarrmv stroIllal cells provide a specific microenvironment 
required for hematopoietic cell development. In addition, proliferation and 
maturation of the committed progenitor cells are govemed by a network of 
hematopoietic growth factors (HGF's) and cytokines (figure 1). A tight balance 
must be maintained to compensate for normal blood cell loss and to meet with the 
deluands of extra cell production during heluatopoietic stress and infectious 
disease. 
1.2 Development of B cell precursors 
When committed to the B cell lineage, primitive lymphoid cells enter a sequence of 
developInental steps, eventually resulting in the expression of functional immu-
noglobulin (Ig) heavy and light chain genes (1,2). Intermediate stages of B cell 
developIllent can be recognized both by characteristic genoillic and phenotypical 
changes. Different nOInenclatures have been used to designate the subsequent 
stages of B cell developInent. In this thesis, the nOIllenclature according to Melchers 
et al is used (figure 2) (3). The most prinlitive stage is represented by the pro-B cell, 
in which the genes coding for Ig~'''T (IgH) and Ig",,, (Igl) chains are still in the non 
rearranged or germ line configuration (figure 2). In the subsequent steps, first the 
Ig heavy chain variable (V) region genes are rearranged. At the pre-B-I cell stage 
one of the diversity (D) genes is juxtaposed to one of the joining 0) genes, with 
deletion of the interspacing DNA (4). This process of DJ,,~,y (OJ,,) chain gene 
rearrangement is followed by fusion of one of the V genes to the rearranged OJ" 
genes to form a continuous VDJ" sequence coding for the variable region of the Ig 
heavy chain protein. 0" to J" joining may give rise to three possible reading frames 
(RF)(5). In productively rearranged VDJ", the OJ" gene is preferentially in RF-1 (6). 
The occurrence of OJ" in RF-3 is cmmter selected by the generation of multiple stop 
codons in the rearranged gene, preventing translation of transcripts to proper 
proteins (5). OJ" in RF-2 may form a DJe" protein which can be incorporated into 
the nlenlbrane, but is unable to give the progression signal for further maturation 
and prevents further rearrangement (7). By joining of OJ" to one of the V genes, the 
cell enters the pre-B-II cell stage. The VDJ" joint is coupled to the gene coding for 
the constant region of the IgM heavy chain. 
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Figure 2 Simplified scheme 
of growth factor responses of 
normal B cell precursors in 
relation to rearrangement 
stahlS of immunoglobulin 
genes. During B cell develop-
ment the genes coding for Ig 
heavy and light chains are 
rearranged in an orderly 
fashion. Rearrangement of the 
Ig light chain will start only if 
the Ig heavy chain gene has 
been successfully rearranged. 
If rearrangement of either 
gene has been unsuccesfu1r the 
cell has the capacity to try 
again. If persistent failure of 
the genes occur, the cell will 
go into apoptosis. In normal B 
cell lymphopoiesis prolifera-
tive responses to HGFs are 
determined by the rearrange~ 
ment status of the Ig genes. 
Also shown are the correspon~ 
ding immunophenotypes of 
acute lymphoblastic leukemia 
cells. (GL ;=; germ~line) 
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Thus, a complete It heavy chain (lgII) is produced. If the rearrangement was non 
productive, i.e. not leading to expression of a VDJC" on the cell membrane, 
additional rearrangements of the VDJ genes may occur on the same or on the other 
allele (8-10) (figure 2). Membrane expression of a properly rearranged VOJC" 
tenninates further VDJ II gene rearrangen1ent, thus preventing continued rearrange-
ment of the VDJ genes on the other allele (allelic exclusion)(ll,12). Because cells 
with VDJ" in RF-2 or RF-3 are underrepresented in number in the pre-B-II cell pool, 
it is assumed that these cells die, or in case of RF-3 shift to RF-1 by continued rear-
rangement (3,6). In mice that are unable to express It-protein due to targeted 
disruption of the It gene, pre-B-I cells numbers are greatly reduced (13). 
The IgII chain is first present in the cytosol, rapidly followed by expression on 
the membrane. Membrane expression of the Ig" chain is possible only in conjuncti-
on with IgL chains. However, in Pre-B II-cells the IgL chain gene is not yet expres-
sed. Instead, the cells express surrogate light chains, encoded by VpteB and As genes 
(14,15). 
It is generally thought that rearrangement of the IgL gene K or A can only be 
initiated after successful rearrangenlent and ll1embrane expression of the IgH chain 
(16-18). 
IgL chain genes rearrange in a siInilar way as the IgH chain genes, but without 
the involvement of D genes, 'which are not present in the light chain loci. Rearran-
gement of the IgL chain genes occurs in the Pre B-II cell stage. Allelic exclusion 
prevents sin1ttltaneous expression of K and A light chains. Currently, this ordered 
fashion of rearrangernents is under some debate since rearrangernent of the K light 
chain gene has been fOlmd in absence of rearrangement of the heavy chain gene 
(19,20). In any case, it seems unlikely that B cells lacking the Ig" genes can persist, 
because in1proper rearrangen1ent of either the 19B or IgL chain genes will arrest 
maturation and induce apoptosis, thereby preventing the accumulation of non 
functional B cell precursor cells (6). Indeed, mice lacking the Ig" chains as a result 
of targeted disruption of the gene, showed a maturation arrest at the pre-B cell 
stage (13). Distinct stages of B cell precursor development are closely linked to 
different response patten1s to exogenous growth stimuli. For instance during 
normal B cell development in mice, cells respond to IL-7 as single growth factor 
after productive rearrangen1ent of the Ig/l chain gene, \-"hile in earliel' stages 
responses are seen only in synergy with other stromal factors (21-23). 
6 Cytokille signalillg alld mitogenic respollsiveuess olB cell preCllrsor acute lymphoblastic lellkemia 
1.3 Acute lymphoblastic leukemia (ALL) 
ALL is a neoplastic disease characterized by the clonal expansion of immature 
lymphoblastic cells. Accumulation of these cells in the bone marrow affects normal 
hematopoiesis. The clinical characteristics of ALL include anemia leading to fatigue 
and pallor, neutropenia with increasing susceptibility to infections, and thrombocy-
topenia resulting in enhanced bleeding tendency. 
Among other prognostic determinants such as white blood cell cOlmt, age at 
diagnosis and cyto-genetics, immtmophenotype has prognostic significance and 
may have implications for the therapeutic approach (24-26). Immunophenoty-
pically, different types of ALL can be recognized: ALL of B cell precursor cells 
(BCP-ALL): null-, conmlOn- ,pre-B- and B-ALL and ALL of the T lineage (T-ALL): 
inunature T-ALL, common thymocyte T-ALL, mature T-ALL. 
Based on imn1unophenotypical characteristics, null- and conunon ALL cells 
may be considered leukemic representants of the normal pre-B-I cells (null-ALL: 
CDlO-, CD19+, CD34+, Cytoplasmic(Cy)" -; c-ALL: CDlO+, CDl9+, CD34+/-, Cy,,-) 
(27)(Fig.2). According to this classification, pre-B ALL cells (CDlO+, CD19+, 
CD34+ / -, Cy,,+ )(27) would be the leukemic representants of pre-B-II cells. B-ALL 
cells (Smlg+)(27) would be leukemic representants of inunature B cells (Fig.2). 
Rearrangement of the IgH chain gene in the absence of actual production of the Igw 
indeed is fotmd in rnost cases of null- and c0I1U11on-ALL (28,29). However} in a 
substantial number of null- and c-ALL cases (9-40%), rearrangement of either the 
kappa or lambda light chain gene is seen, which would be expected to be seen only 
in pre-B II cells that express fl protein (28,30,31). By definition pre-B ALL cells 
express functionally rearranged IgH genes. This would imply that the correlation 
behveen in111Utnophenotype and the corresponding rearrangement status seen in 
normal B cell precursors is frequently lost in acute lymphoblastic leukemia. 
If BCP-ALL cells wOllld behave like I'epreselltallts of 1I0rlllai developlllelital stages of B cells 
alld if ill 111111'"11 alld lIIice a sill/ilar developll/e/!t dependent growth factor respollse patte/'ll 
exists, aile wOllld expect BCP-ALL cells to respolld to IL-7 as sillgle growth stillluills ill pre 
B ALL, or ill sYllergy with either IGF-l or KL ill Illill-ALL or c-ALL. Whether these phello-
typically de filled II/atumtioll stages of ALL have differellt reqllirelllellts for growth factor 
still/Illatioll, has Ilot beell establioshed. This qllestioll has bee/! addressed ill Chapter 2. 
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1.4 Hematopoietic growth factor (HGF) and cytokine 
responses of normal and leukemic BCP 
7 
Most HGFs are active in more than one hematopoietic differentiation lineage 
and/ or at multiple stages of maturation. HGFs that govem the development of 
lymphoid cells show this pleiotropy as well. For instance, interleukin (IL-) 7 is a 
mitogenic factor for B cell precursor (BCP) cells, thymocytes and cytotoxic T cells 
(32-36) and in vitro experiments suggest a role for IL-7 in the rearrangement 
process of the T cell receptor gene (37-39) and possibly the IgH chain gene in BCP 
cells (40). 
In the mouse model, the response of BCPs to IL-7 was shown to depend strictly 
on the Ig rearrangement status (21,41). BCP cells become responsive to IL-7 in 
synergy with Kit Ligand (KL) during IgH chain gene rearrangement, to IL-7 as 
single growth stimulus during Ig, chain genes rearrangement and finally lose the 
capacity to respond to IL-7 after succesful rearrangelnent of IgH and Igl chain genes 
(figure 2) (21,41-46). 
Insulin-like growth factor (IGF-l) is a potent growth stinlulus at the pro-B cell 
stage, but not in the more mature stages of B cell development (47,48). Other HGFs 
of which mitogenic effects in BCP cells have been reported are IL-2 and IL-3 
(49-51). 
Opposite effects of HGFs on normal and leukemic BCP cells have been reported 
as well. For instance, proliferation of both normal and leukemic BCP cells is 
inhibited by IL-4. In contrast, IL-4 induces proliferation in mature B cells in synergy 
with CD40 activation (36,52-55). Modulation of effects of other cytokines is a 
characteristic feature of Inost HGFs. 
Failure to respolld to specific growth alld differelltiatioll factors durillg specific stages of 
maturatioll or excessive syllthesis of growth factors may call tribute to leukemogemsis. III 
experimelltal models it was showll that ullcolltrolled syllthesis of HGFs may lead to the 
developmellt of leukemia. For illstallce, the overexpressioll of IL-7 may result ill leukemia 
alld lymphomas (60,61). Recwtly, the expressioll of multiple growth factors ill leukemic 
cells was reported, but its relevallce for developmellt of disease still has to be established -
(62-64). 011 the other !wlld leukemic trallsformatioll may result ill growth factor respollses 
differellt from Ilormal. The experimellts described ill chapters 2 alld 3 were pelJol'II/ed to 
compare the proliferative respollses of BCP-ALL cells to differellt growth stimuli with those 
of Ilormal BCP cells. 
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1.5 Effects of Interleukin 7 in combination with other growth 
stimuli on normal and leukemic BCP cells 
1.5.1 Interiel/kill 7 
IL-7 induces proliferation in normal and malignant BCP cells during distinct stages 
of development. Originally, IL-7 was considered BCP growth factor and have a role 
in maintenance of BCPs to compensate for the high loss of cells during the 
inefficient re-arrangement procedure. IL-7 induces N-myc expression (65,66), 
downregulates expression of genes involved in Ig gene reconlbination events 
RAG1 and RAG2 genes as well as the gene coding for terminal deoxynucleotidyl 
transferase (TdT)(67). Based on these results, it has been suggested that IL-7 also 
promotes the differentiation of BCP cells. 
Recently a role of IL-7 in promotion of rearrangement of the Ig heavy chain 
gene has been suggested as well (40). The function of IL-7 in B cell development 
was further elucidated in mice lacking the IL-7R a chain gene. In these mice both B 
and T cell developnlent ·was severely unpaired. B cell developnlent was arrested at 
the pre-B-I cell stage of maturation, whereas T cell development was affected 
before CD4 and CD8 expression and before rearrangement of the T cell receptor j3 
chain (68). Similar results were found in mice deficient of IL-7 either by disruption 
of the IL-7 gene or by continuous application of IL-7R neutralizing antibodies 
(69-71). Strikingly, some mature peripheral Band T cells were still detectable, 
suggesting that Band T cell development without tl1e involvement of IL-7 is possi-
ble. However, it remains to be determined whether these lymphocytes are fully 
ftmctional. The important role of IL-7 in T proliferation and differentiation of 
thymocytes and cytotoxic T cells (37, 72-76) underlines the pleiotropic features of 
IL-7. 
1.5.2 CD20 and CD40 activatiol1 in BCP cells 
CD20 is an integral membrane protein exclusively expressed on BCP cells and 
mature B cells, but not plasma cells. No natural ligand is known and its precise 
function is uncertain, although the structure of CD20 suggests a function as ion 
charmel (88). In support of the latter motion, a role for CD20 in transmembrane 
Ca" fluxes in Band T cells was demonstrated (89). Activation of CD20 by 
monoclonal antibodies induces cell cycle pl'Ogression from GO to G1, but in synergy 
with e.g. CD40, CD20 activation elicits a full mitogenic signal in B lymphocytes 
(90,91). 
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Differentiation and proliferation of BCP cells is dependent on cell-cell contact, 
allowing membrane botmd ligands to bind to their receptors. CD40 is a receptor 
already expressed at an early stage of B cell development. Its ligand is expressed 
on activated T cells (92). Activation of CD40 in normal BCP cells induces prolifera-
tion in synergy with other growth stimuli like IL-3, IL-7 or IL-I0 (93,94), suggesting 
a role of activated T cells in B lymphopoiesis (95). 
1.5.3 Balle marl'Ow sfl'Oma a11d Bep cells 
Proliferation and differentiation of normal IlUtrine and hUIl1an BCP cells is 
dependent on the bone marrmv micro environn1ent. Although stron1al cells 
produce many of the growth factors involved in lymphopoiesis like IL-7, KL and 
IGF-l, these cytokines cmmot completely replace the role of stromal cells 
(32,46,48,77,78). In vitro culture systems using bone marrow stromal cells showed 
that the differentiation of murine BCP cells is dependent on direct contact with the 
stromal cells (79-82). Similar in vitro culture systems for human BCP cells 
permitted some proliferation, but not differentiation (82-86). Moreover, these 
cultures of BCP depended on the presence of considerable concentrations of fetal 
calf serun1 or horse serun1~ contaminating the culture systeIH with undefined 
growth Ill0dulatory substances. Only recently a sentnl free in vitro culture system 
using hUInan fetal bone Inarrow has been proposed that allows for differentiation 
of hematopoietic stem cells to lymphoid cells and differentiation of BCP cells to 
mature B cells (87). 
One of the I110lecules expressed on bone I11arrOW stronla cells and involved in 
cell to cell contact is FLK2/FLT3 ligand (FL)(96, 97). Binding of FL to its tyrosine 
kinase receptor (FLK2/FLT3) induces proliferation of hematopoietic stem cells and 
committed progenitors (98-102). FL itself, but much more strongly in synergy with 
IL-7 and KL, supports the proliferation and limited differentiation of B cell proge-
nitors (98, 100,103,104). However, addition of human bone marrow stroma cells 
greatly enhances both proliferation and differentiation (103), indicating that still 
other bone Inarrow stroma components are active in BCP development. The effects 
of FL on the proliferation of BCP-ALL cells have also been studied to some extend. 
These experiInents revealed a heterogeneous stinlulation pattenl with induction of 
DNA synthesis in response to FLT3 activation in a minority of the samples tested. 
Interestingly in some cases synergy was observed with IL-7, but not with KL, IL-3 
or IL-6 (105,106). 
Experimellts dealillg with the role of CD20 alld CD40 activatioll 011 proliferatioll of ALL 
cells ill coll1billatioll with other still1l1li are presellted ill chapter 3. 
10 Cylokille sigllfllillg fllld mitogenic responsiveness of B cell precllrsor aClIte lymphoblastic leukemia 
1.6 The IL-7 receptor complex 
HGFs act on cells through binding to specific membrane receptors. Receptors for 
most HGFs form a superfamily of integral membrane glycoproteins based on struc-
tural homologies of the extracellular but not the cytoplasmic domains (107-109). 
The extracellular domains of members of this family contain in general foUl' highly 
conserved cystein residues and a five residue motif of Trp-Ser-X-Trp-Ser (WSXWS) 
within a region of approximately 200 amino acids (110,111) . This region is called 
the Cytokine Receptor Homology domain (CRH) and is crucial for ligand binding. 
The IL-7R is a heteromeric complex, comprising the IL-7R a chain and the 
common Y (y,) chain. IL-7R a chains display a low affinity for IL-7 (112,113). Only in 
combination with the y chain, the high affinity binding site is formed (114). The 
presence of the y, chain in the complex is also essential for proliferative signaling 
(115-117). The y, chain is a common receptor chain for multiple receptors, including 
those for IL-2, IL-4, IL-9 and IL-15. 
The human IL-7R a chain is a protein of 459 amino acids with a predicted 
nlolecular weight of 75 kD and is expressed on BCP cells} filature and inmlature T 
cells and on monocytes and macrophages (112,113,118,119). Alternative splicing 
can generate three IL-7Ra transcripts} encoding a soluble receptor and hvo menl-
brane-bowld forms: one fully length, the other with an altered, tnmcated 
cyotoplasmic domain. Both membrane bound forms bind IL-7 ,but only the full 
length form is capable of signal transduction (112). 
In the intracellular part of certain HGF receptors} conserved stretches of amino 
acids can be recognized designated respectively boxes 1, 2 and 3 (120,121). Boxes 1 
and 2 are involved in mitogenic signaling (120,122-126), while the fWlction of box 3 
remains obscure. :tvloreover} these regions are most likely involved in binding of 
signaling molecules. The intracellular part of the IL-7R contains the box 1 consen-
sus sequence formed by amino acids 269 to 282. In the IL-7R, box 2 and box 3 
consensus sequences are lacking. Furthermore, the cytoplasnlic dornain of the 
IL-7R a chain contains three tyrosine residues at positions 401,449 and 456. 
Phophorylated tyrosine residues form potential recruitment sites for intracellular 
molecules containing Src homology-2 (SH2) or protein tyrosine binding (PTB) 
domains (127, 128). 
The possibility that ALL cells may overexpress jlll/ctiol/ally iI/active splice variallts oj the 
IL-7Ra chain, has been investigated. These experiments are presented ill chapter 2. 
Cltapter 1 11 
1.7 Signaling through the IL-7 receptor complex 
Like other HGF-Rs, the IL-7R complex does not contain intrinsic tyrosine kinase 
domains, but recruitment of cytoplasmic protein tyrosine kinases (PTKs) enables 
rapid tyrosine phosphorylation of a broad set of protein substrates, including the 
IL-7Ra chain itself (109,129-134). Three major signaling routes generally involved 
in HGF and cytokine signaling that depend on protein tyrosine phosphorylation 
have been identified: 1) the JAK/STAT pathway 2) the Ras/ MAPK pathway and 
3) the Phosphatidylinositol- 3-kinase (PI3-kinase) pathway. These three pathways 
have also been found to playa major role in IL-7 signaling (figure 3). 
Constitutive association of JAK family members to HGF receptors prior to 
ligand binding has been demonstrated (135-140). JAK kinases bind to the membra-
ne proximal cytoplasmic region of receptor proteins (137,139,141-143). This 
nlembrane proxiInal region, containing box 1 and box 2 Illotifs, is essential for 
mitogenic signaling following receptor activation (124,125,144-147), suggesting a 
critical role of JAK tyrosine kinase activation in nlitogenesis. 
In hetermneric receptor complexes the individual receptor chains have different 
specificity for JAK binding and activation. The IL-7R complex has been shown to 
activate JAKI and JAK3 in T cells (148). JAK3 binds to the common y chain and 
JAKI to the IL-7R a chain (148). Activation is thought to occur via cross-
phosphorylation of the JAK proteins that are brought in each other's proximity as 
the result of receptor complex formation (149-151). 
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Figure 3a JAKI and JAK3 
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activated resulting in the tyrOSine 
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Figure 3b: following receptor binding IRSl/2 becomes phosphorylated on tyrosines and in turn form 
new docking sites. Grb2/S0S will be activated through binding to IRSl/2 and potentially activate the 
Ras signaling pathway resulting in activation of gene transcription. PI3-kinase can either be activated 
through binding to the phosphorylated receptor tyroSine 449 or through binding to the activated 
IRSl/2 molecule. Activation of IRSl/2 is mas likely terminated by binding of the protein tyrosine 
phosphatase Syp to IRSl/2, which on itself is ivolved in activation of p21 Ras by recruitment of 
Grb2/S0S complex. 
Following JAK activation, STAT (Signal Transducer and Activator of Transcription) 
proteins will be tyrosine phosphorylated and form complexes through P-Tyr/SH2 
interactions (152,153). STAT complexes will translocate to the nucleus and bind to 
specific consensus DNA sequences in the promotor regions of cytokine inducible 
genes. Tyrosine phosphorylation of STAT molecules suffices for STAT dimerization 
and DNA binding, but to activate transcription the STAT complex needs to be 
phosphorylated on serine residues as well (154,155). Until now six different STAT 
family members have been identified and implicated in HGF signaling, but the 
formation of homo- and heterodimeric STAT complexes may further expand the 
ftmctional diversity of STATS. Different combinations of STAT molecules are 
involved in signaling through different cytokine receptors although extensive 
overlap in STAT activation exists (156). Binding affinity of STAT complexes for 
specific DNA sequences depends on the STAT complexes formed. Together with 
the cell-type specific expression and activation of STAT molecules this determines 
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the response specificity to various cytokines in cells of different ongm or in 
different stages of differentation. Receptor specific STAT activation and complex 
formation was originally thought to be regulated by the specific activation of the 
JAK/Tyk kinase family (153,157,158). Recently however it was suggested that 
specificity of activation of STAT molecules is largely determined by recruitment to 
1110dular tyrosine based 1110tifs in the signal-transducing receptor components 
(142,159-164). 
Other substrates for at least two members of the JAK kinase family (JAK1 and 
JAK3) are insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) and PI3-kinase . The 
JAK kinases may physically bind to IRS1/2 and possibly playa role in tyrosine 
phosphorylation of these molecules (165,166). 
IRS-1 is a 130 KDa protein that is activated upon stimulation of the insulin 
receptor or IGF-1-R. Activation of IRS-1/2 also plays a crucial role in signaling via 
the IL-2R, IL4-R, IL-7R, IL-9R and the IL-15R (165,167). IRS-1/2 contains 18 
potential sites for tyrosine phosphorylation from which at least 6 sites serve as sites 
for SH2 domain containing proteins. IRS-1/2 has an ATP binding site that is 
homologous to the ATP binding site in the kinase domain of JAK1 but does not 
have kinase activity itself. Upon receptor activation, IRS-1/2 is directly phospho-
rylated and serves as a docking molecule for SH2 domain containing proteins, e.g. 
kinases, phosphatases like Syp and other docking molecules like Nck. In addition, 
IRS-1/2 binds the Ras pathway activating complex Grb2/S0S and the p85 subtmit 
of PI3-kinase. The binding of the p85 subunit of PI3 kinase and the Grb2/S0S 
cOll1plex results in activation of both complexes. 
A second 11lajor pathway involved in cytokine receptor signaling is the p21 Ras 
dependent MAPK (Mitogen Activated Protein Kinase) pathway (168-175). Ras is a 
GTPase and has a critical role in proliferation control. With the activation of Ras a 
phosphorylation cascade of molecules participating in the Ras signaling chain is 
started, resulting in the phosphorylation of MAPK. Activated MAPK translocates 
to the nucleus and activates transcription either direct or indirect by activation of 
nuclear transcription factors. 
Following receptor activation phosphorylated tyrosine residues can interact 
with the Src homology 2 (SH2) adaptor protein Shc, which in turn will become 
tyrosine phosphorylated (176-179). The Grb2-S0S complex connects with phospho-
rylated Shc, upon which the catalytic acitvity of SOS becomes activated and in turn 
activates Ras by ex-changing GDP for GTP (176,179-181). However, IL-7 induces 
MAPK activation independent of Shc (182), suggesting the use of alternative 
MAPK activation pathways e.g. via PI3-kinase or IRS-1/2 (183-186). Alternatively, 
JAK1 and JAK2 have been found directly associated with Grb2/S0S, offering 
another potential Shc independent mechanism of Ras activation (187-189). 
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PI3-kinase is a protein complex that comprises a p85 regulatory and pllO katalytic 
subunit. PI3-kinase is as a serine/threonine kinase involved in phospholipid 
metabolism and most likely in mitogenic signaling. Importantly, PI3-kinase is 
activated in response to IL-7 and coupled to the IL-7R, either directly via associa-
tion with the IL-7R alpha chain (190-192), indirectly via interaction with the Src 
kinase p59',n, via both mechanisms (193-195). For association of PI3-kinase to the 
IL-7Ra, phosphorylation of tyrosine 449 (Y449) of the IL-7Ra chain was shown to 
be indispensible (40). Both prevention of tyrosine phosphorylation and substitution 
of Y449 for phenylalanine completely inhibited P13-kinase activity and prolifera-
tion (40). The role of PI3-kinase in proliferative signaling in B cells is further 
demonstrated by the complete block of IL-7 induced proliferation by the specific 
PI3-kinase inhibitor Wortm3!min (40,196). Moreover, IL-7 induced proliferation is 
completely inhibited in cells bearing the IL-7Ra/Y449F mutant, but the capacity to 
rearrange the IgH chain gene leading to B cell differentiation was preserved, 
suggesting that differentiation occurs independently of PI3-kinase activation (40). 
The role of p59',n in B cell development is still tmclear. The cytoplasmic tail of 
the IL-7R recruits p59"n constitutively in a SH2 independent way (194). PI3 kinase 
binds to the IL-7R associated p59"n through its SH3 domain (193,197,198). Upon 
activation of the IL-7R, both PI3-kinase and PS9',n become activated as well (193). 
However, mice lacking p59"n by targeted disruption of the coding gene, show 
nornlal B cell developnlent and B cell nlediated inunune responses are not affected 
in these animals (199). In addition, normal numbers of ftmctional peripheral T cells 
are generated, implicating that T cell development is not strictly Fyn dependent 
(199,200). 
In different cell types the association of Grb2 and 50S to PI3 kinase was demon-
strated, suggesting possible activation of the Ras pathway (183,201-204). Illustra-
tive for the cOlllplex nature of these signaling routes is the observation that the 
reverse yctivation route was demonstrated as well: PI3-kinase activation by Ras 
(184,185,205). 
Defects ill dowllstream sigllalillg evellts lIIigllt COli tribute to loss of mitogellic cOlltml alld 
illability to differelltiate. To illvestigate 1101'11101 sigllalillg properties of tile sillgle 1111111011 
IL-7R a clio ill we cOllstructed a cllillleric receptor cOlltaillillg tile cytoplaslllic alld 
tl'OlISlllelllbl'OlIe part of tile IL-7R and tile extracellular part of tile III lilian G-CSFR. 
Lack of lIIitogellic response ill a subset of BCP-ALL patiellts was slloWII 1I0t to be due to 
defective expressioll of lIIelllbers of tile IL-7R cOlllplex. We tllerefore illvestigated sigllalillg 
rolltes after activatioll of tile botll tile lIatllrallL-7R and tile cllimeric receptors. Resllits alld 
implicatiolls are disClissed ill cllapters 4 alld 5. 
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1.8 Relevance of in vitro proliferation in clinical practice of acute 
leukemias 
The biological significance for HGFs in normal hematopoiesis is well established. In 
leukemia control over proliferation and differentiation is lost. This might result in 
or be the result of aberrant responses to HGFs. In vitro proliferation assays have 
been used to study the responses of leukemic cells to various HGFs. In acute 
myeloid leukemia (AML), in vitro proliferation in absence of HGFs is an unfavora-
ble prognostic factor for relapse after remission (206). 
Proliferatioll alld differelltiatioll of B cell precllrsor cells ill vivo reqllire presellce of HGFs. 
III vitro pl'Dliferatioll respollses of aCllte lymphoblastic lellkemia cells ill absellce or presellce 
of cytokilles are highly hetel'Dgelleolls. III chapter 6 we have attempted to correlate ill vitl'D 
HGF respollses of ALL to clillical olltcollle. 
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Abstract 
Interleukin 7 (IL-7) stimulates proliferation of normal human and murine B cell 
precursor (BCP) cells in a distinct fashion, depending on the stage of maturation of 
the cells. For instance, the productive rearrangement of the immlffioglobulin heavy 
chain gene has been demonstrated to be essential for the response of BCP cells to 
IL-7 as the single proliferation stimulus. IL-7 activates a receptor that consists of the 
IL-7R protein and the conunon y chain (yJ BCP acute lymphoblastic leukemia 
(BCP-ALL) cells variably respond to IL-7. Among 72 cases of BCP-ALL IL-7 
activated DNA synthesis in 34. In 4 cases inhibition of DNA synthesis was seen. In 
the remaining 38 cases IL-7 exerted no effects. We determined whether this 
heterogeneity in IL-7 response could be correlated with parameters that could 
influence the IL-7 response. First we show that, in contrast to the murine BCP cells, 
the IL-7 response of human BCP-ALL cells did not correlate with the status of IgH 
chain gene rearrangement and expression, nor with the rearrangement of IgL chain 
genes. Subsequently, it is demonstrated that IL-7R protein and transcripts as well 
as y, transcripts are equally present in the IL-7 responsive and nonresponsive BCP-
ALL samples, indicating that the defective expression of these chains could not be 
held responsible for IL-7 response failures. Finally, we observed that Kit Ligand 
(KL), known to synergize with IL-7 in the most primitive stages of normal B cell 
development, did not enhance the IL-7 responses of BCP-ALL cells. 
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2.1 Introduction 
In the majority of patients with acute lymphoblastic leukemia (ALL), the leukemic 
cells express features of B cell precursors (BCP) (1). The regulation of proliferation 
and survival of BCP-ALL cells remains poorly understood. Previous studies in 
relatively small series of patients have indicated that BCP-ALL cells display largely 
heterogeneous responses to IL-7, a growth factor for murine and human BCP cells 
(2,3). Growth stimulation by IL-7 was observed only in a subgroup of patients, 
whereas in others no or even inhibitory effects of IL-7 on proliferation were seen 
(4,5). Explanations for this heterogeneity have not been provided. 
In normal B cell development in mice, IL-7 responses of BCP have been found to 
correlate with the status of rearrangement and expression of Ig heavy (Ig") and Ig 
light (Ig,) chain genes (6,7). Murine pro-B cells with germ line IgH genes do not 
proliferate in response to IL-7 despite the presence of IL-7 receptor proteins on the 
cell membrane (8,9). During the first maturation step, OHJH joining takes place, 
which may occur in three different reading frames, RFl, RF2 or RF3. BCP cells at 
this stage of maturation synergistically respond to IL-7 in combination with kit 
ligand (KL), also known as stem cell factor (SCF) and other stroma derived 
components (10,11,12,13). OJ" rearrangement in RF2 may result in the production 
of OJHC" protein (14). It has been suggested that OJC" protein blocks further 
maturation by preventing VH to OJ" joining (14,15). Upon joining of VH to OJ", BCP 
cells enter the next maturation stage (6,7,8,16). When VOJ" rearrangement is 
productive, cells express the fl protein in the cytoplasm. BCP cells expressing fl 
have been reported to become responsive to IL-7 as the single growth stiInulus, 
while they have lost responsiveness to KL (6,8,9,16). In agreement with this, Era et 
al. demonstrated that 11 chain expressing transgenic mice show selective expansion 
of IL-7 dependent BCP (17). Finally, upon the expression of the immunoglobulin K 
or A light chain genes, IL-7 responsiveness is lost (6,17,18). The molecular 
mechanisms responsible for these distinct IL-7 responses are not yet known. 
IL-7 binds to a membrane receptor of the superfamily of hematopoietic growth 
factor and cytokine receptors (19,20,21). Molecular cloning of the human IL-7 
receptor (IL-7R) revealed the existence of 3 different isoforms, one being a soluble 
protein, resulting from alternative RNA splicing (22). Recently, it has been 
demonstrated that IL-7R chains form heteromers with the y chain common to IL-2R 
and IL-4R (y,) and that interaction with y, is a prerequisite for high affinity IL-7 
binding (23,24). 
In the present study, we have investigated to which extent IL-7 responses of 
BCP-ALL cells from individual patients correlate with biological parameters 
characteristic of the different stages of normal B cell development. We show that 
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IL-7 induces a proliferative response in approximately 50% of the BCP-ALL cases. 
No correlation is apparent between the (lack of) IL-7 response and immunopheno-
type (Null-ALL, Common-ALL, Pre-B-ALL) and KL does not stimulate DNA 
synthesis of BCP-ALL cells, neither alone nor in combination with IL-7. In addition 
it is demonstrated that the ability of BCP-ALL cells to respond to IL-7 as a single 
growth stimulus is neither determined by Ig gene rearrangement status nor by IL-
7R/y, expression levels. 
2.2 Materials and Methods 
BCP-ALL mId Ilormal BCP samples 
ALL cell samples were isolated from bone marrow or peripheral blood by Ficoll-
Hypaque (Nygaard, Oslo, Norway) density gradient centrifugation as described 
previously (25). T cells were removed from the ALL cell samples by E-rosette 
formation using 2-aminoethylisothiouronium bromide (AET) treated sheep red 
blood cells, followed by sedimentation through Ficoll-Hypaque (26). Monocytes 
were removed by adherence to plastic petri dishes at 31'c for 1 hour. Informed 
consent was given in all cases. All BCP-ALL cell samples were subjected to routine 
diagnostic immuno phenotyping. Leukemic cells were subclassified as null-ALL 
(CDlO-, CDl9+, CD34+, Cy" -), common-ALL (CDIO+, CD19+, CD34+i-, Cy,.-) or 
pre-B ALL (CDlO+, CD19+, CD34+i-, Cy,.+) (27). For additional analyses, the cells 
were either used fresh or after cryopreservation using a controlled-freezing 
apparatus (Planer Biomed, Sunbury-on-Thames, UK)(25). 
Nonleukemic BCP were isolated from normal bone marrow using a three-steps 
purification protocol. First, low density cells were recovered after Ficoll-Hypaque 
separation. Next, CD3 expressing T lymphocytes and CD14 and CD15 expressing 
myelomonocytic cells were removed from this fraction by antibody and 
complement mediated cytolysis as described (28). Finally, COlO expressing cells, 
labeled with monoclonal antibody J5 (Becton-Dickinson, Mountain View, CAl and 
goat-anti-mouse Ig antibodies coupled to fluorescein isothiocyanate (GAM/ 
FITC,Nordic, Tilburg, The Netherlands) were sorted using a FACS 440 cell sorter 
(Becton Dickinson, Sunnyvale CAl. 
III vitro clIitllre alld growth factors 
DNA synthesis was assessed by uptake of 'H-Thymidine ('H-TdR, specific activity 
2 Ci/mmol, Amersham International, Amersham, UK) as described (29). In brief, 
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0.2 X 10' cells were cultured in triplicate in 96 wells dishes (Greiner, Alphen a/ d 
Rijn, the Netherlands) for 3 and 7 days in 100 ~IL serum-free culture medium (30). 
Eighteen hours before harvesting on nitrocellulose filters using a Titertek cell 
harvester (Flow Laboratories, Isrike UK) 0.1 ~ICi 'H-TdR was added to the cultures. 
Human recombinant IL-7 and KL (gifts from Immunex Corp., Seattle, WA) were 
added to the cultures at final concentrations of 100 U /mL and 100 ng/mL, 
respectively. 
Expression of IL-7R and COlli ilion yellains 
Expression of IL-7R protein was assessed by flow cytometry (FACScan) following 
labeling of cells with anti human IL7 receptor monoclonal antibody M21 (Imrnunex 
Corp., Seattle, WA) and Goat anti mouse immunoglobulin coupled to fluorescent 
isothiocyanate (GAM/FlTC, Nordic Tilburg, The Netherlands). The presence of 
IL-7R and y, chain ,vas assessed by reverse transcriptase polYlnerase chain reaction 
(RT-peR) analysis. For this purpose, RNA was isolated from bone marrow samples 
by guanidine thiocyanate/phenol chloroform extraction (31). Human IL-7R cDNA 
was PCR amplified with the forward primer CTCCAGAGATCAATAATAGCTC 
and reverse primer TTGTCGCTCACGGTAAGTTCA. y, cDNA was PCR amplified 
using forward primer GAGCAAGCTTCATGTTGAA-GCCATCATTACC and 
reverse prinler GCCTGAAACCTGAACCCCAAGCTTCTGA. Control reactions on 
H,o were performed to exclude possible contamination of PCR reagents and 
primers with DNA. 
Soltthem and RT-PCR analysis of il1l1l1llllogloblilin ge!/es 
DNA was isolated from ALL cells as described previously (32,33) Ten micrograms 
of DNA were digested ·with appropriate restriction enzylnes. The restriction 
fragments were size fractionated on agarose gels and transferred to Hybond' nylon 
membranes (Amersham) as described (32,34). For analysis of the fl gene configura-
tion, DNA was digested with BglII, BamHI and HindIlI or Sac! and BamHI. The 
blots were hybridized with JH probes EcoRI/BglII (2.5 Kb), EcoRI/HindIll (0.9 Kb) 
of the clone H24 (a gift from Dr. T.Honjo, Kyoto University, Japan) (35) or with the 
IGHJ6 (1.0 Kb EcoRI/HindIlI fragment)(36). For analysis of the K gene rearrange-
ments, DNA was digested with Sac!, Bgi II, or Hind III and hybridized with IgK 
probes: HindIII/EcoRI (0.5 Kb), Sac! (1.8 Kb) or EcoRI (2.5 Kb), ( Dr. Ph. Leder, 
Harvard Medical School, Boston MA)(37) or with the IGKJ5 probe (0.5 Kb 
HindIII/Sac! fragment)(38). Rearrangement of the lambda light chain gene was 
analysed by digestion of DNA with EcoRI and hybridization with a BglII/HindIlI 
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fragment (l.4Kb) of the Hu lambda C2 clone (Dr. Ph. Leder)(39). Probes were "P-
labeled by random priming (40). For RT-PCR analysis, three primers were used to 
amplify transcripts of either D]Cf' or VD]Cf' rearranged 19B genes. One forward 
primer matched the V H framework region 3 consensus sequence CTGTCGACA-
CGGCCGTGTATTACTG. The second forward primer matched the]H framework 
region 4 consensus sequence GGTCACCGTCTCCTCTAGAGT (41). The reverse 
primer TGCCAGCTGTGTCGGACATGAC was chosen in the fourth exon of the C. 
region. The applicability of these primers was verified on positive (B cell lines) and 
negative (granulocytes) control samples. In addition, H,G control reactions were 
performed to exclude contamination of PCR reagents and primers with DNA. 
2.3 Results 
IL-7 respollses of BCP-ALL cells 
IL-7 responses 'H-TdR uptake assay of 72 cases of BCP-ALL are shown in Table 1. 
In 38 cases, IL-7 failed to induce a proliferative response. In 4 cases of common 
ALL, IL-7 even inhibited spontaneous 'H-TdR uptake. In 34 cases, IL-7 stimulated 
DNA synthesis. Stimulation values (IL-7 supplemented versus nonsupplemented 
controls) were variable and ranged from 1.5 (defined as the lowest level of 
stimulation) to 37.8 (mean: 4.4, median: 2.2). Cases in which IL-7 induced DNA 
synthesis were equally distributed over the different immunophenotypical sub-
types of BCP-ALL. 
Table 1 Proliferative response of BCP-ALL cells to interleukfn-7 
Immunological Subtype* Number of Effect of IL-7 on DNA Synthesis in vitro 
patients 
Stimulation Inhibition None 
Null-all 6 3 0 3 
Common-all 48 23 4 21 
Pre-B-all 18 8 0 10 
See materials and methods for detailed immunophenotype 
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Kit-ligalld (KL) syllergizes with IL-7 ill stimulatillg DNA sYllthesis ill 1I0rmai bllt 1I0t ill 
leukemic Bep 
KL has been shown to synergize with IL-7 in inducing proliferation of BCP in mice 
(10-12,42). Using highly purified human normal BCP, we obtained comparable 
results (Table 2). In contrast, in 11 cases of BCP-ALL, no enhancement of IL-7 
stimulation by KL was seen (Table 2). 
Table 2 
Sample! No Factor IL-7 
Patient 
NORMAL 1 138 ±36$ 1054 ± 95 
BCP I1 2 190 ± 91 671 ± 124 
'------------1------- -------
NULL-ALL DH 15531 ± 683 14748 ± 191 
BU 663 ± 59 2692 ± 210 
------------
1-------- --------
Commonwall IR 378 ± 43 268 ± 57 
KA 2575 ±312 2617 ± 194 
KE 1644 ± 163 1793 ± 66 
PE 250 ± 38 2231 ± 207 
VW 4397 ± 123 12028 ± 1070 
---------- ------ 1-------
Prewbwall LAC 2875 ± 152 2948 ± 121 
VS 42 ±5 568 ± 37 
KT 282 ± 23 2734 ± 180 
UR 578 ± 42 7487 ± 389 
SP 1967 ± 151 5301 ±74 
FACS purified, see Materials and Methods 
JH-TdR uptake; mean cpm ± SD of triplicate cultures 
Irradiated (25 Gy) cells 
KL KL + IL-7 Irrad.' 
546 ± 148 2349 ± 695 42± 10 
1146 ± 196 3359 ± 346 20±3 
------ ------- 1--------
16704 ± 1052 16381 ± 1212 788 ± 250 
740 ± 47 2717 ± 255 50± 12 
------- ------- 1-------
482 ± 90 266 ± 34 159 ± 28 
2407±361 2813 ± 172 33± 2 
1955 ± 102 2007 ± 106 60± 14 
196 ± 19 2130 ± 36 89 ±35 
9332 ± 1045 12385 ± 248 34±4 
-------1--------!-------
2817 ± 211 2891 ± 269 105 ± 40 
215 ± 18 1512 ± 203 60± 15 
274 ± 14 2687 ± 218 36 ±9 
597 ± 48 9300 ± 1209 52± 13 
1543 ± 66 4653 ± 233 56 ± 19 
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Expressioll of IL-7R alld commoll ychaills 
To examine whether a lack of IL-7 responsiveness of nCP-ALL cells could be 
explained by the absence of an IL-7R, expression of both IL-7R and y, chains was 
studied. In seven IL-7 nonresponsive cases, IL-7R could be readily detected by flow 
cytometry using anti-IL-7R MoAb. A representative example of the analysis (Fig 1) 
shows that the expression levels of IL-7R on IL-7 responsive versus IL-7 
nonresponsive nCP-ALL cells does not differ. Further, RT-PCR revealed that the 
IL-7R "ivild type form (H20), rather than the truncated (HI) or the soluble (H6) 
splice variants (22), is predominantly expressed in nCP-ALL cells (Fig 2). 
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Figure 1 Representative FACS analysis of IL-7 receptor expression in nCP-ALL cells (A) responsive 
and (8) nonresponsive to IL-7 
Transcripts of the y, with the expected size of the wild type form were apparent in 
both IL-7 responsive and nonresponsive nCP-ALL cell samples (Fig 3). Collective-
ly, these findings indicate that the failure of nCP-ALL cells to respond to IL-7 
cannot be attributed to the lack of expression of IL-7R and y, genes, or the over-
expression of nonftmctional splice variants. 
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Figure 2 RT-PCR analysis of JL-7R expression in BCP-ALL cells. To visualize lowly expressed splice 
variants, agarose gel separated products were blotted on Hybond+ membrane, hybridized with a np 
labeled human IL-7R probe and autoradiographed. Results of 15 representative cases are shown either 
responding (R) (lanes 2,3,8,11 and 13) or nonresponding (N) (lanes 1,4-7,9,10,12 and 14) to stimulation 
with IL-7 
o 0 
to z 
w 
n. 
RNNRRRNNNNNNRRNR 
- IL-2Ry 
Figure 3 RT-PCR analysis of y, chain expression in IL-7 responding (R) (lanes 1,4-6,13,14,16) and 
nonresponding (N) (lanes 2,3,7-12,15) nCP-ALL cells. 
COllfiguratioll of illlllllllZOglohulill gelles 
The configuration of the Ig heavy chain and the Ig K and Ie light chain genes was 
investigated by Southern analysis in 16 IL-7 responsive and 13 IL-7 nonresponsive 
BCP-ALL cases. In all cases, one or both alleles of the IgH gene had been rearranged 
(Table 3). RT-PCR analysis using a VH consensus forward primer and a CH reverse 
primer showed that in all cases investigated the rearrangement consisted of V H to 
DJH joining (Fig 4). 
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Southern blot analysis showed Ig, chain gene rearrangements in 50% of the BCP-
ALL patients analyzed responding to IL-7 and in 62% of those not responding to 
IL-7 (Table 3). 
Table 3 
Il~7 responsive 11-7 non responsive 
IgH chain gene Cases (n"16) C1ses (n=13) 
Germ line: (GG) 0 0 
Rearranged: (RR, GR, GO, DR) 16 13 
Ig), and K chain gene 8 5 
Genu line A and/or K. (GG) 
Rearranged i .. and/or rearranged or deleted K- 8 8 
(GR, GO, DR, DO, RR) 
, 
Compilation of data denved from Southern blot analyslS. For details see Matenal and 
Methods G: genu line, R: rearranged, D: deleted 
::J w w :3 0 l: 0 0 :Il s2 OJ Q. 
'" 
OJ c fE z 
'" 
(f) 
-VDJ-Cr< 
R R R R N N N N N N N 
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Figure 4 RT -peR analysis of rearrangement and expression of IgH chain genes in nCP-ALL cells. 
RNA was isolated from IL-7 responding and nOll responding cases and after eDNA synthesis subjected 
to peR. Panel A shows products of RT-PCR with the V H fOr\vard primer and C Il specific reversed 
primer. All cases tested showed VD] rearrangement. Panel B shows products of RT-PCR with the 
specific]H fOr\vard primer and C Il primer. 
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Discussion 
Over the years, the understanding of the growth control of BCP-ALL cells has 
ren1ained very Ihnited. Froll1 the increasing list of recombh1ant grmvth factors and 
cytokines that have become available during the last decade, only IL-3 and IL-7 
consistently evoke mitogenic responses in BCP-ALL cells, albeit not in all cases (2-
5). In this study comprising 72 BCP-ALL cases, including both childhood and adult 
ALL, we have found that only in about one half of the cases (n=34) a proliferative 
response to IL-7 is elicited in vitro. In an attempt to explain this heterogeneity, a 
number of potential mechanisms that might determine or influence the 
responsiveness of BCP-ALL cells to IL-7 have been investigated. With progression 
of B cell differentiation, which is tightly correlated with the rearrangement and 
expression of Ig heavy and light chain genes, BCP have been reported to display 
distinct response patterns to IL-7 alone or in cmnbination with other stimuli such as 
KL and insulin-like growth factor-l (IGF-l) (43,44). We therefore set out to examine 
whether the differences in responses of BCP-ALL cells to IL-7 and KL (and IGF-l) 
could also be related to the status of Ig genes. Southern blot analysis showed that It 
heavy chain gene rearrangement had occurred in all of 23 cases (12 IL-7 respon-
ders, 11 nonresponders), indicating that in neither of these samples the BCP-ALL 
cells had been arrested at the pro-B cell stage. This would fit with the observation 
that IGF-l, which has been shown to specifically stimulate proliferation in pro-B 
cells but not in more advanced stages of B cell development (43,44), failed to 
induce a proliferative response in BCP-ALL cells in combination with IL-7 (data 
not shown). Further analysis of the ft gene rearrangement status by RT-PCR using 
V Hand JH consensus primers indicated that V H to OJ" joining had taken place in all 
of these BCP-ALL samples. Ouring normal B cell development, BCP lose their 
responsiveness to KL after VOJ" joining has occurred (14,15). Therefore, it is not 
unexpected that BCP-ALL cells also failed to respond to this growth factor (Table 
2). A number of studies have indicated that BCP that have undergone successful 
VOJ" joining, resulting in the expression cytoplasmic 11 proteins, are highly 
responsive to IL-7 as the single growth stimulus (6,8,16,17). It was suggested that 
the presence of It chains but not yet Ig, chains in the cytoplasm enhances the IL-7 
driven proliferation of BCP, and that BCP with nonproductive VOJ" rearrange-
ments would thus be hampered in their response to IL-7 (7). This hypothetic 
mechanism could also account for the loss of IL-7 responsiveness following the 
production of Ig light chains, by assuming that light chain complex formation with 
the It chains abolishes the enhancing effects of single J.l chains on IL-7 induced 
proliferation (7). Our observations in BCP-ALL cannot be reconciled with trus 
ll1odel, since a) IL-7 responses were seen in cases with null and common ALL, i.e., 
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leukemic immunophenotypes characterized by nonproductive VD]H rearrange-
ments and b) the rearrangement status (and potential expression) of the Ig light 
chain genes also failed to show a correlation \vith IL-7 responsiveness. . 
Transforming growth factor 13 (TGF 13) has been shown to inhibit IL-7 induced 
proliferation of normal BCP (6,45). Because normal and leukemic B cells can 
synthesize TGF 13 (46,47), we have investigated whether TGF 13 may have interfered 
with IL-7 responses of BCP-ALL cells in DNA synthesis assays. Howevel~ addition 
of TGF 13 neutralizing antibody to the culture medium did not result in an increase 
of IL-7 induced proliferation in BCP-ALL cells, indicating that IL-7 responses had 
not been blocked by endogenously produced TGF 13 (data not shown). 
Finally, we have studied whether IL-7 nonresponsive BCP-ALL cells lack 
functional IL-7 receptors. By FACS analysis using anti IL-7R antibodies, IL-7R 
protein could be detected on IL-7 nonresponding BCP-ALL cells. Because three 
IL-7R isoforms exist, including a nonsignaling soluble form (22), we investigated 
the expression distribution of these splice variants by RT-PCR. No indication was 
found for overexpression of any of the two nonsignal transducing IL-7R fonns in 
these cells. By a sinlilar RT-PCR based approach, we excluded that a lack of 
expression of the y, could have been responsible for the failure of BCP-ALL cells to 
stinmlation with IL-7. 
In conclusion, in contrast to obscrvations in 111urine BCP, our studies have 
shown that heterogeneous IL-7 responses of BCP-ALL cells do not correspond to 
distinct stages of B cell maturation and status of the Ig genes. It is at present not 
clear whether this lack of correlation is an aberrant characteristic of the leukclnic 
cells or whether it reflects the more complex IL-7 responses of human BCP cells as 
compared with murine BCP. Irrespective of this and because IL-7 response failures 
did not correlate with the lack of expression of IL-7R and. Y" it will now be 
important to investigate the differences in activation of signaling molecules in IL-7 
responsive and nonresponsive BCP-ALL cells. 
Cllflpter 2 41 
References 
1. Pui C.H, Behm FG, Crist WM. Clinical and biological relevance of immunologic marker studies 
in childhood acute lymphoblastic leukemia. Blood 1993;82:343-362. 
2. Namen AE, Lupton 5, HjerriJd, Wignall J, Mochizuki DY, Sdunierer A, Mosley il, March q, 
Urdal 0, GillisS, Cosman D, Goodwin RG. Stimulation of B-cell progenitors by cloned murine 
interleukin-7. Nature 1988;33:571-573. 
3. 5aeland S, Duvert V, Pandreau 0, Caux C, Durand I, Wrighton N, Wideman J, Lee F, Banchereau 
J.lnterleukin-7 induces the proliferation of normal human B-cell precursors. Blood 1991;78: 2229-
2238. 
4. Skjonsberg C, Erikstein BK,Smeland EB, Lie SO, Ftmderud S, Beiske K, Blomhoff HK. Interleukin-7 
differentiates a subgroup of acute lymphoblastic leukemias. Blood 1991;77:24,15-2450. 
5. DigeJ W, Schmid M, Heil G, Conrad P, Gillis 5, Porzsolt F. Human interleukin-7 induces 
proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood 
1991;78:753-759. 
6. Lee G, Namen AE, Gillis 5, Ellingsworth LR, Kincade PW. Normal B cell precursors responsive to 
recombinant murine IL-7 and inhibition of IL-7 activity by transforming growth factor-b. 
J.Immunol. 1989;142:3875-3883. 
7. Hardy RR, Carmack CE, Shin ton SA, Kemp JD, Hayakawa K. Resolution and characterization of 
pro-B and pre-pro-B cell stages in normal mouse bone marrow. J.Exp.Med. 1991;173:1213-1225. 
8. Sudo T, Ito M, Ogawa Y, Ilzuka M, Kodama 1'1, Kunisada T, Hayashi 5-1, Ogawa M, Sakai K, 
Nishikawa S, Nishikawa 5-I. Interleukin 7 production and function in stromal cell-dependent il 
cell development. J.Exp.Med.1989;170:333-338 
9. Hayashi 51, Kunisada T, Ogawa M, Sudo T, Kodama H, Suda T, Nishikawa 5, Nishikawa SI. 
Stepwise progression of B lineage differentiation supported by interleukin 7 and other stromal 
cell molecules. J.Exp.Med. 1990;171:1683-1695. 
10. McNiece IK, Langley KE, Zsebo Klvl. The role of recombinant stem cell factor in early B cell 
development. }.ImmunoJ. 1991; 146:3785-3790. 
11. Funk PEl Varas A, Witte PL. Activity of stem cell factor and IL-7 in combination on normal bone 
marrow B lineage cells. J.ImmunoJ. 1993;150:748-752. 
12. Rolink AI Streb M, Nishikawa 5, Melchers F. The c-kit encoded tyrosine kinase regulates the 
proliferation of early pre-B cells. Eur.J.lmmunol. 1991;21:2609-2612 
13. Palacios R, Nishikawa S. Developmentally regulated cell surface expression and function of c-kit 
receptor during lymphocyte ontogeny in the embryo and adult mice. Development 
1992;115:1133-1147. 
1<1. Gu H, Kitamura D, Rajewsky K, B cell development regulated by gene rearrangement: arrest of 
maturation by membrane-bound D",protein and selection of DH element reading frame. Cell 1991; 
65:47-54. 
15. Melchers F, Karasuyama H, Haasner 0, Bauer S, Kudo A, SakaguchiN, Jameson B, Rolink A. The 
surrogate light chain in B-cell development. Immtmology Today 1993;14:60-68. 
42 Cytokille signaling alld mitoge/lic respOllSiVC1IeSs alB cell precursor awfe lympllOblastic leukemia 
16. Faust EA, Saffran DC, Toksoz 0, Williams DA, Witte ON. Distinctive growth requirements and 
gene expression patterns distinguish progenitor B cells from pre-B cells. J.Exp.Med. 1993;177:915-
923. 
17. Era T, Ogawa M, Nishikawa S-I, Okamoto M, Honjo T, Akagi K, Miyazaki J-I, Yamamllra K-1. 
Differentiation of growth signal requirement of B lymphocyte precursor is directed by expression 
of immunoglobulin. EMBO J. 1991;10:337-342. 
18. Henderson AT, Narayanan R, Collins L, Dorshkind K. StahlS of kL chain gene rearrangement and 
c-kit and IL-7 receptor expression in stromal cell-dependent pre-B cells.J.Immunol. 1992; 
149:1973-1979. 
19. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. 
Proc.NatI.Acad.Sci. 1990;87:6934-6398. 
20. Cosman D, Lyman SO, Idzerda RL, Beckman MP, Park LS, Goodwin RG, March CJ. A new 
cytokine receptor superfamily. Trends Bioch Sci 1990;15:265-70. 
21. Cosman D. The hematopoietin superfamily. Cytokine 1993;5:95-106. 
22. Goodwin RG, Friend 0, Ziegler SF,Jerzy R, Falk BA, Gimpel 5, Cosman 0, Dower SK, March KJ, 
Namen AE, Park LS. Cloning of the human and murine interleukln-7 receptors: demonstration of 
a soluble form and homology to a new receptor superfamily. Cell 1990;60:941-951. 
23. Kondo M, Takeshita T, Higuchi M, Nakamura M, Sudo T, Nishikawa S-I, Sugamura K. 
Functional participation of the IL-2 receptor g chain in IL-7 receptor complexes. Science 
1994;263:1453-1454. 
24. Noguchi M, Nakamura Y, RuseH SM, Ziegler SF, Tsang M, Cao X, Leonard WJ. Interleukin-2 
receptor I chain: a functional component of the interleukin-7 receptor. Science 1993;262: 
1877-1880. 
25. Touw I, Groot-Loonen J, Broeders L, van Agthoven TIl, Hiihlen K, Hagemeijer A, Lowenberg B. 
Recombinant hematopoietic growth factors fail to induce a proliferative response in precursor 
B acute lymphoblastic leukemia. Leukemia 1989;3:356-362. 
26. Madsen M, Johnsen HE, Wendelboe HP, Christiansen SE. Isolation of human T and B 
lymphocytes by E-rosette gradient centrifugation. Characterization of the isolated 
subpopulations. J.Immunol.Methods 1980;33:323 
27. Dongen JJM van, Adriaansen HJ, Hooijkaas H. Immunophenotyping of leukemias and non-
Hodgkin's lymphomas. Immunological markers and their CD codes. Neth J Med 1988;33: 
298-314. 
28. Bot FJ, Eijk L van, Broeders L, Aarden LA, Lowenberg B. Interleukin-6 synergizes with M-CSF in 
the formation of macrophage colonies from purified human bone marrow progenitor cells. Blood 
1989;73:435-437. 
29. Oelwel R, Salem M, Pellens C, Dorssers L, Wagemaker G, Clark S, Lowenberg B. Growth 
regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in 
a serum free culture system. Blood 1988;72:1944-1949. 
30. Touw I, Pauwels K, Agthoven T van, Gurp R van, Budel L, Hoogerbrugge H, Dehvel R, 
Goodwin R, Namen A, Lowenberg B. Interleukin-7 is a growth factor of precursor Band T acute 
lymphoblastic leukemia. Blood 1990;11:2097-2101. 
Chapter 2 
31. Chromczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium 
thiocyanate-phenol-chloroform extraction. Anal Sioch. 1987;162:156-159. 
32. Miller SA, Dykes DO, Polesky HF. A simple salting out procedure for extracting DNA from 
human nucleated cells. Nucleic Acids Res 1988;16:3. 
33 Dongen J.J.M. van, Wolvers-Tettero I.L.M. Analysis of immunoglobulin and T-cell receptor 
genes. Part I: basic and technical aspects. Clin Chim Acta 1991;198:1-91 
34. Southern EM. Detection of specific sequences among DNA fragments separated by gel 
electrophoresis. J Mol BioI 1975;98:503-517. 
35. Takahashi N, Nakai S, Honjo T. Cloning of human immunoglobulin m gene and comparison 
with mouse m gene. Nucleic Acids Res 1980;8:5983-5991. 
43 
36. Beishuizen A, Verhoeven MJ, Mol EI. Breit TM, Wolvers-Tettero ILM, Dongen JJM van. Detection 
of immunoglobulin heavy-chain gene rearrangements by southern blot analysis: 
recommandations for optimal results. leukemia 1993;7:2045-2053. 
37. rIieter PA. Maizel JV Jr, Leder P. Evolution of immunoglobulin kJ region genes. J BioI Chern 
1982;257:1516-1522. 
38. Beishuizen A, Verhoeven MJ, Mol EI. Dongen J1M van. Detection of immunoglobulin Kappa-
light-chain gene rearrangement patterns by southern blot analysis. Leukemia 1994;8: in press. 
39. Hieter PA, Hollis GF, Korsmeyer SJ, Waldman TA, Leder P. Clustered arrangement of 
immunoglobulin I constant region genes in man. Nature 1981;294:536-540. 
40. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease 
fragments to high specific activity. Anal Biochem 1983;132:6-13. 
41. Steenbergen EJ, Verhagen 0JHM, Leeuwen EF van, Borne AEGKr von dem, Schoot CE van der. 
Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute 
lymphoblastic leukemia. Blood 1993;82:581-589 
42. Martin FH, Suggs SV, Langley KE, Ltt HS, Ting J,Okino KH, Morris CF, McNiece IK, Jacobsen 
FW, Mendiaz EA, Birkett NCr Smith KA,Johnson MJ, Parker VP, FloresJC, Patel AC, Fisher EF, 
Erjavec HO, Herrera C], Wypych J, Sachdev RK, Pope JA, Leslie I, Wen 0, Lin C-H, Cupples RL, 
Zsebo KM. Primary structure and functional expression of rat and human stem cell factor DNAs. 
Cell 1990;63:203-211. 
43. Landreth KS, Narayanan R, Dorshkind K. Insulin-like growth factor-I regulates pro-B cell 
differentiation. Blood 1992;5:1207-1212. 
44. Gibson LF, Piktel D, Landreth KS. Insulin-like growth factor-I potentiates expansion of 
interleukin-7 -dependent pro-B cells. Blood 1993;82:3005-3011. 
45. Israels LG, Israels SJ, Begleiter A, Verburg L, Schwartz L, Mowat:MRA, Johnston JB. Role of 
transforming growth factor-_ in chronic lymphocytic leukemia. Leukemia Research 1993;17: 
81-87. 
,16. Kehrl JI-I, Taylor AS, Delsing GA, Roberts AB, Sporn MB, Fauci AS. Further studies of the role of 
transforming growth factor-beta in human B cell function. J Immunol. 1989;143:1868-1874. 
47. LagnealLx L, Delforge A, Dorval C, Bron D, Stryckmans P. Excessive production of transforming 
growht factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits 
growth of hematopOietic precursors and interleukin-6 production. Blood 1993;82:2379-2385. 

Chapter 3 
CD20 and CD40 mediated mitogenic responses in 
B-lineage acute lymphoblastic leukemia 
Frans]. Smierl,g, Marieen vall Paassell iJ, Karel Hiilz/ed', Bob Lowenbergf] 5, 
Iva P. TOllwiJ .5 
'Sophia Childrm's Hospital,"DrDalliel dell Hoed Callcer Cell tel', Erasmus Ulliversity, 
'Dept. of Hematology, Rotterdam, The Netherlallds. 
46 Cytokille signnlillg alld mitogenic responsiveness ofR cell precursor aCllte lymphobJastic leukemia 
Abstract 
Activation of CD20, a cross-nlenlbrane ion chaIU1el, induces cell cycle progression 
from G" to G1 in B lymphocytes. Subsequent activation of CD40, a membrane receptor 
of the nerve growth factor superfamily, transits the B cells to the S phase. CD40 may 
also act synergistically in combination with IL-4 (B-lymphocytes) or IL-3/IL-7 (B-cell 
precursors). We investigated the prolilerative responses of B-lineage acute 
lymphoblastic leukaemia (ALL) cells to CD20/CD40 activation. In 18/56 ALL cases 
CD20 activation resulted in significant increases in DNA synthesis. Sinlilar, although 
more moderate, effects were seen of activation of CD40 in 10/44 cases. Responses to 
CD20 or CD40 activation were independent of co-stimulation with IL-3, IL-4 or IL-7, 
and various cocktails of the different growth stimuli did not act synergistically. 
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3.1 Introduction 
B cell development is governed by an as yet incomplete characterized series of 
haematopoietic growth factors and other stimuli. Factors that exert growth 
stimulatory effects on normal B cell precursors include interleukin (IL)-3 and IL-7 
(1-4). 
CD20 is a 35/37 kD surface polypeptide expressed exclusively on B cells. Onset of 
expression of CD20 takes place before the appearance of cytoplasmic ft chains and is 
sustained during B-cell development lUltii the plasma cell stage (5,6). In normal B 
lymphocytes, activation of CD20 proteins with the antibody IF5 induces cell cycle 
transition from Go to G, but is not sufficient to initiate DNA synthesis (7-11). Acti-
vation of CD20 results in its phosphorylation on serine and threonine residues (12,13) 
and increases the influx of Ca" ions into the cells. The structural and nmctional 
properties of CD20 indicate that the protein acts as a cross-membrane ion chaIUlel 
(14,15). 
CD40 is a receptor of the nerve growth factor receptor superfamily aIld is expressed 
on B cells, follicular dendritic cells, normal basal and thymic epithelium and several 
carcinoma and melanoma cell lines (16-18). During B cell development, the 
appearance of CD40 on tile cell membrane precedes the expression of CD20 and 
immlUloglobulin heavy chains (19). Activation of CD40 by either tile CD40 ligand or 
CD40 activating antibodies, in concert with IL-4, induces proliferation and 
maturation of B-lymphocytes (20-24). Also, co-activation of CD20 and CD40 results in 
a full mitogenic response of B lymphocytes (25,26). B cell precursors (BCP) proliferate 
in response to CD40 activation only when co-stimulated Witil IL-3, IL-7 or IL-lO 
(27,28). 
Here, we studied the proliferation inducing effects of CD20 and CD40 activation on 
B-lineage aeute lymphoblastic leukemia (ALL) cells, alone and in combination with 
growth factors (IL-3, IL-4 and !L-7). Activation of CD20 resulted in a proliferative 
response of ALL cells in 18/58 (31%) cases; activation of CD40 induced DNA 
synthesis in 10/44 (23%) cases. With the exception of one case, no synergistic effects 
of the various stimuli were seen. TI,ese data show that responses of ALL cells to 
CD20/CD40 activation are heterogeneous and distinct from those of normal (pre-)B 
cells. 
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3.2 Materials and Methods 
lsoiatioll of cells 
ALL cells were isolated from bone marrow or peripheral blood by Ficoll-Hypaque 
(Nygaard, Oslo,Norway) density gradient centrifigation as described previously (29). 
T cells were removed from the ALL cell samples by E-rosette formation using 2-
aminoethylisothiouroniwn bromide (AET) treated sheep erythrocytes, followed by 
sedimentation through Ficoll-Hypaque (30). Monocytes were removed by adherence 
to plastic petri dishes at 31' C for 1 h. In all cases, informed consent was obtained. The 
ALL cell samples were subjected to routine diagnostic inununophenotyping with a 
panel of monoclonal antibodies (MoAb). Six cases were classified as null-ALL 
(patients 1-6), 36 as common-ALL (patients 7-41, 58), 11 as pre-B-ALL (patients 42-52) 
and 5 as B-ALL (patients 53-57) according to established criteria (31). Cells were used 
either fresh or after cryopreservation using a controlled-freezing apparatus (Planer 
Biomed, Stmbury-on-Thames,UK) (29). Enriched fractions of normal peripheral blood 
B-lymphocytes were obtained using the same protocol. 
DNA sYllthesis assay 
DNA synthesis was assessed by uptake of'H-Thymidine ('H-TdR, specific activity 2 
Ci/nunol, Amersham International, Amersham, UK) as described (32). In brief, 0.2 x 
10' cells were cultured in triplicate in 96 wells dishes (Greiner, Alphen al d Rijn, The 
Netherlands) for 3 and 7 days in 100 flL serum free medimn (33). Eighteen hours 
before harvesting on nitrocellulose filters using Titertek cell harvester (Flow Labora-
tories, Irvine) 0.1 flCi 'H-TdR was added to each well. 'H-TdR incorporation was 
measured by liquid scintillation COWlting. 
Growth factors alld CD20 or CD40 activatillg alltibodies 
Human IL-3 (Gist Brocades, Delft, The Netherlands) was used at 100 U IMI; hwnan 
IL-4 (Dr S. Clark, Genetics Institute Cambridge, MA) was added to the cultures at a 
1:5000 dilution of Cos cell supernatant; hmnan IL-7 (Dr. L. Park, IInmwlex Corp., 
Seattle, WA) was used at 100 U/MI. Anti-CD40 monoclonal antibody (MoAb) 14G7, 
provided by Dr. R.A.W. van Lier (Central Laboratory of the Red Cross Blood 
Transfusion Service, Amsterdam) was used at a 1:250 dilution of ascites. The C020 
activating MoAb IF5 (7, 9)(0r. E.A. Clark (University of Washington, Seattle, WA) 
was used at a final concentration of 3 Ilg/ml. 
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AlIalysis of C020 alld C040 expressioll 
Expression of C020 or C040 was assessed by flow cytometry (FACScan) after 
labelling of cells with either tile anti C020 MoAb lFS (9) or the activating anti-C040 
antibody 14G7 and goat anti-mouse imImmoglobulin coupled to fluorescin isothio-
cyanate (GAM/FITC, Nordic Tilburg, The Netherlands). 
Table 1 Proliferative responses of ALL cells to activation of CD20 in comparison to responses to 
JL-3 or IL-7" 
PI ALL subtype No additive AnH·CD20 IL-3 IL-7 Irradiated 
to cuI hue cells' 
I Null 1.3±0.6· 10.9±1.7 3.7±1.8 2.4±0.4 0.4±0.1 
6 Null 1O.7±0.2 2S.2±6.5 50.8±7.6 18.0±1.2 0.7±0.1 
10 Common 18A±O.6 29.8±0.9 31.8±1.0 22.4±2.0 OA±O.l 
13 Common 8.8±0.2 59.1±1.6 18.4±1.3 17.1±1.7 O.6±O.1 
15 Common 13.0±0.8 55.5±5.5 23.3±3.0 20.3±1.0 O.2±O.O 
16 Common 13.4±0.9 20.6±3.1 n.d.s 17.2±1,0 O.2±O.O 
22 Common 3.8±0.1 9.3±2.1 18A±4.2 6.3±0.5 OA±O.2 
30 Common S.9±O.2 6S.9±I1 11.4±2.2 1O.1±1.8 O.7±O.2 
31 Common 5.9±0.5 78.2±7.2 20,O±2,1 27.3±3.5 O.5±O.2 
32 Common 3.1±O.3 8.1±2.2 14.8±4.6 18.2±OA O.3±O.1 
58 Common 7.9±1.3 27.0±2.7 9,8±2,7 6A±1.1 0.3±O.1 
36 Common 2.6±0.4 13.1±2.3 6,6±2,O 2.3±O.6 O.7±O.1 
38 Common 7.1±2.2 14.7±3.3 21.0±6.9 10.3±1.9 lA±O.2 
43 Pre-B 10.5±1.8 23.3±6,0 18.9±S.1 19.1±1.4 1.0±0.0 
44 Pre-B 29,6±1.9 87.3±9,7 S8.1±1D 69.3±3.0 0.3±O.2 
45 Pre-B 19.3±1.0 39,0±8.0 27.5±1.4 31.0±3.4 O.3±O.2 
50 Pre-B 2,2±0.6 24,9±1.0 6.6±1.4 2.2±OA O.4±O,l 
57 B 19.4+1.8 32.0±1.0 273±14.7 19,6+6,0 0,9+0.2 
" Only cases responsive to CD20 activation have been included.In these cases, stimulation values 
(IFS supplemented versus non-supplemented controls) were >1.5. 
Data are from "1-I-Thymidine uptake assays and are expressed as mean cotmts per minute x 100 ± 
standard deviation of triplicate cultures, 
Cells were irradiated (2SGy) before culture, 
Not Determined 
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3.3 Results and Discussion 
CD20 activatioll of ALL cells 
Dose titration experiments performed with ALL cells from four patients indicated 
that maximal stimulation of ONA synthesis is seen at IF5 concentrations of 1-10 
mg/mL. A representative experiment is shown in Fig lA. Parallel incubations with 
control MoAb antibody did not result in mitogenic responses (data not shown). 
Proliferative response to IF5 (3 mg/mL) were analysed in 58 cases of ALL. C020 
activation resulted in a significant increase of ONA synthesis in 18 cases (Table 1). 
The (in)ability of IF5 to induce DNA synthesis did not correlate with the 
immunologic subtype of ALL. Therefore differences of maturation or phenotype of 
ALL did not explain the heterogeneity in responses to C020 activation. A correlation 
was neither apparant between responses to C020 activation nor responses to IL-3 or 
IL-7 (Fig 2). In fact, the random distribution of the plotted stimulation indices 
indicates that each of tile individual responses is independent from any of the 
responses to the other growth stimuli. As expected, flow cytometric analysis with 
anti-C020 showed that ALL cells of IF5 responding cases expressed C020. In 15/27 
IF5 nonresponders analysed, the ALL cells expressed CD20, indicating that in these 
cases ti,e absence of response to IF5 was not caused by lack of C020. 
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Figure 1 Response of Illunan BCP-ALL cells to titrated dosages of the CD20 activating MoAb lF5 in a 
1--I-TdR uptake assay. 
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Table 2 Proliferative response of ALL cells to activation of CD40 in comparison to responses to IL-3, 
IL-7 and CD20 activation@ 
51 
PI ALL No additive to Irradiated 
1 
11 
8 
14 
21 
26 
30 
48 
50 
52 
55 
• 
subtype culture AnU-CD40 IL-3 IL-7 AnU-CD20 cells' 
Null 1.3±0.6· 9.6±2.4 3.7±1.S 2.4±0.5 10.9±1.7 0.4 
Null 35.4±1.5 70.8±3.1 121±4 33.5±0.2 35.8±1.4 0.4 
Common 349±22 568±45 341±8 336±12 389±8 0.6 
Common 5.5±0.9 15.6±3.6 15.0±2.0 5.9±1.6 3.8±1.2 0.4 
Common 5.6±O.6 32.3±1.3 16.8±1.9 12.2±1.5 8.9±1.2 0.2 
Common 31.5±1.0 45.5±3.9 35.2±1.6 27.0±1.7 32.9±0.4 1.4 
Common 5.9±0.2 12.4±1.9 1l.4±2.1 10.1±1.8 65.9±11 0.7 
Pre-B 17.6±3.9 28.9±0.8 25.7±1.1 10.7±4.0 19.8±1.2 0.4 
Pre-B 2.2±O.6 5.5±O.2 6.5±1.4 2.2±0.4 24.9±1.0 0.3 
Pre-B 3.2±O.O 8.0±0.6 16.2±2.3 2.0±OA 3.6±1.3 0.6 
B 1.8+0.0 5.0+0.3 1.8+0.5 2.0+0.2 1.9+0.3 0.4 
Only cases responsive to CD40 activation have been included. In these cases, stimulatIon values 
(14G7 supplemented versus non-supplemented controls) were >1.5. 
Data are from JH-'Olymidine uptake assays and are expressed as mean cotmts per minute x 1000 ± 
standard deviation of triplicate cultures. 
Cells were irradiated (25Gy) before culture. 
CD40 activalioll of ALL cells 
In dose titration experiments, maximal stimulation of DNA synthesis by CD40 
activating antibody 14G7 was reached at dilutions of 1:1000-1:250 (Fig IB). In 10/44 
ALL cases, DNA synthesis was moderately enhanced by 14G7 (1:250 dilution, Table 
II). Previously, Law et 01(34) could not demonstrate mitogenic effects of CD40 
activation in ALL cells. However, the latter study was based on the analysis of eight 
cases of ALL only (34). The various immunological subtypes off B -cell ALL were 
represented among the 10 14G7 responsive cases. No correlation was apparant 
between responses to anti-CD40 and those to IL-3, IL-4, IL-7 or anti-CD20 (Fig 2). All 
immunological subtypes of B cell ALL were present among the 10 14G7 responsive 
cases. No correlation was apparent between responses to anti-CD40 and those to IL-3, 
IL-7 or anti-CD20. 
All 14G7 responders expressed CD40 at levels detectable by flow cytometry. In 6/8 
14G7 nonresponders, ALL cells expressed CD40, suggesting that in the majority of 
cases non-responsiveness of ALL cells following CD40 stimulation is due to inef-
fective signalling. 
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Activatioll ofCD20 alld CD40 ill combillatiollwith other stimuli 
Certain stimuli act synergistically in inducing proliferative responses in nonleukemic 
(pre-) B cells. Particularly, this has been demonstrated for the combined activation of 
CD20 and CD40 (25,26), and for activation of CD40 in combination with IL-4 
(20,22-24), IL-3 or IL-7 (28). Proliferative responses of ALL cells to different combi-
nations of stinluli, in the context of activation of CD20 or CD40, are sunlmarized in 
Table III. Although additive effects (lF5 + IL-3; IF5 + IL-7; IF5 + 14G7) were occasi-
onally seen, none of the combinations tested were synergistic, except in a single case 
of ALL in which both the combinations 14G7 + IL-3 and 14G7 + IL-7 synergistically 
stimulated DNA synthesis. 
The response of ALL cells to activation of CD20 or CD40, with or without the 
addition of cytokines, differ from those of nonleukaemic (pre-)B cells. Whether this 
would indicate that ALL cells generally display aberrant responses to CD20 and 
CD40 activation is not clear. In normal B lymphocytes activation of CD20 induces 
transition from GO to Gl (7,9-11), whereas CD40 activation promotes the transition 
from Gl to S phase of the cell cycle. Activation of both of these molecules is required 
for transduction of a full mitogenic signal (25,26,35). The observation that in certain 
cases ALL cells proliferate in response to either CD20 or CD40 activation as a single 
growth stimulus could be suggestive of a partial loss of cell cycle control bypassing 
the necessity of cooperation of signals for a nlitogenic response. Further elucidation of 
signalling properties of CD20 and CD40 in nomlal and leukaemic (pre-)B cells is 
needed to clarify these issues. 
lF5 
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Figure 2 Proliferative responses of BCP-ALL cells in response to different growth stimuli plotted as 
stimulation indices (SI) in matrix mode. SI of IF5 (top panel) or 14G7 (lower panel) on the Y-axis are 
plotted against SI of IL-3, IL-4, JL-7 and 14G7 on the X-axis. 51 higher than 1.5 was defined as stimulation, 
whereas values less than 0.6 were defined as inhibition. 
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Table 3 Swnmary of proliferative responses of ALL cells to different stimuli 
Stimulus Frequency of response (%) Type of response 
IL-3 31/58 (53%) Stimulation 
JL-7 24/58 (41%) Stimulation 
IL-4 2/49 (4%) Stimulation 
22/49 (45%) Inhibition 
MoAb IFS (CD20 activation) 18/58 (31%) Stimulation 
Moab 14G7 (CD40 activation) 10/44 (23%) Stimulation 
IFS + JL-3 22/36 (61%) Additive responses in 4 cases; 
no synergy 
IFS + JL-7 25/50 (50%) Additive responses in 9 cases; 
no synergy 
IFS + 14G7 22/36 (61%) Additive response inS cases; 
no synergy 
14G7 + lL-3 
14G7 + IL-7 
14G7 + lL-4 
Acknowledgments: 
6/12 (50%) 
5/12 (42%) 
2/11 (18%) 
5/11 (45%) 
Synergistic response in 1 case 
Additive response in 2 cases; 
synergistic response in 1 case 
Stimulation; no additive or 
synergistic responses 
Inhibition 
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Abstract 
Interleukin-7 (IL-7) stimulates the proliferation of normal and leukemic Band T cell 
precursors and T lymphocytes. Activation of the JAK/STAT pathway has been 
implicated in IL-7R signaling. We investigated which STAT complexes are formed 
upon stimulation of B cell precursor acute lymphoblastic leukemia (BCP-ALL) 
cells with IL-7. Gel retardation assays with STAT-binding oligonucleotides showed 
that IL-7 induces the formation of two major STAT complexes in BCP-ALL cells. 
Supershifts with anti-STAT antibodies identified these as STA Tl and ST A T5 
complexes. This pattern of STAT activation was seen in all BCP-ALL cases that 
respond to IL-7 in proliferation assays. 
IL-7 also induced STAT/DNA binding in BCP-ALL cases that failed to proliferate 
in response to IL-7, suggesting that the ability of IL-7R to activate the JAK/STAT 
pathway per se is not sufficient for proliferation induction. To determine the contri-
bution of the cytoplasmic domain of the IL-7 receptor a chain (IL-7Ra) to activation 
of STAT proteins, transfectants of the murine pro-B cell line BAF3 were made that 
express chinleric receptors consisting of the extracellular donlain of hunlan 
granulocyte colony-stimulating factor receptor (G-CSF-R} and the transmembrane 
and intracellular domains of human IL-7Ra. Activation of the chimeric G-CSF-
R/IL-7Ra with G-CSF resulted in a full proliferative response and induced the 
phosphorylation of JAKI but not JAK2. Major STAT complexes activated by G-
CSF-R/IL-7Ra contained STA Tl or STAT5, while some formation of STA T3-contai-
ning complexes was also seen. These findings establish that STATl and STAT5, 
and possibly STAT3, are activated upon stimulation of precursor B cells with IL-7. 
The data further indicate that the IL-7Ra chains are directly involved in the 
activation of JAKs and STATs and have a major role in proliferative signaling in 
precursor B cells. 
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4.1 Introduction 
Interleukin 7 (IL-7) is a growth factor for Band T cell precursors and mature T-
lymphocytes'. IL-7 also stimulates the proliferation of leukemic B cell precursors 
(BCP) in certain cases of acute lymphoblastic leukemia (BCP-ALL)". The effects of 
IL-7 on BCP-ALL cells are diverse. Only in a subgroup of patients, IL-7 induces a 
proliferative responseJ, This heterogeneity cannot be ascribed to variations in IL-7 
receptor expression, nor does it correlate with the maturation status of the ALL 
cells'. These observations suggest that differences in the expression or function of 
molecules involved in IL-7 signal transduction determine the variation of IL-7 
responsiveness among BCP-ALL patients. 
The IL-7 receptor (IL-7R) consists of at least two distinct sublmits, a unique u. chain, 
and a common y chain (y,) also present in IL-2R, IL-4R, IL-9R, IL-13R and IL-ISR 
complexes'. Chemical cross-linking with radioactive IL-4 and IL-7 indicated that 
the y, chain associates with IL-4R and IL-7Ru. chains via binding to the respective 
ligands"'. The cytoplasmic region of the y, chain is required for IL-7-induced 
proliferation"'''. After stimulation of T cells 01' B cell precursors with IL-7, a number 
of cellular proteins are rapidly phosphorylated on tyrosine residues". 
Tyrosine kinases of the Janus kinase OAK) family playa crucial role in mitogenic 
signaling from a variety of hematopoietic growth factor (HGP) and cytokine 
receptors"'''. JAK proteins are phosphorylated within minutes after binding of 
HGFs to their respective receptors. The JAKs then phosphorylate proteins known 
as signal transducers and activators of transcription (STATs). Activated STAT 
proteins form complexes that translocate to the nucleus, where they interact with 
specific DNA sequences and control gene expression. IL-7 has been shown to 
activate both JAKI and JAK3 in T cells". It was demonstrated that JAK3 is activated 
via binding to the y, chain. By analogy with the IL-2R, it was suggested that JAKI is 
activated via binding to the IL-7Ru. chain". Zheng et aJ. have recently reported that 
STATI is tyrosine-phosphorylated upon stimulation of a helper-T cells with IL-7". 
In contrast, other investigators have shown that STAT3 and STATS, but not STATI, 
are activated by IL-7 in peripheral blood lymphocytes (PBL)"'. Peptide competition 
experiments performed by this group further suggested that a domain containing a 
tyrosine present in the membrane-distal cytoplasmic region of the IL-7Ru. protein 
serves as a docking site for STAT proteins'". No information is available regarding 
the activation of STAT proteins by IL-7 in precursor B cells. 
In this study, we have examined which STATs are activated by IL-7 in leukemic B 
cell precursors. We first show that both STATI and STATS are activated upon 
stimulation of human BCP-ALL cells with IL-7. By using transfectants of the 
murine pro-B cell line BAF3, we then demonstrate that chimeric G-CSF-R/IL-7Ru. 
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proteins~ containing the transn1embranc and cytoplasn1ic don1ains of IL-7Ra~ are 
capable of transducing proliferative signals, activating JAK1, and inducing the 
formation of ST A Tl-, ST A T5- and possibly also STA T3-containing complexes. 
4.2 Materials and methods 
Isolalioll of CP-ALL cells were isolated from bone marrow by Ficoll-Hypaque 
(Nygaard, Oslo, Norway) density centrifugation. T cells were removed from the 
ALL cell samples by E-rosetting with 2-aminoethylisothiouronium bromide (AET)-
treated sheep red blood cells, followed by sedimentation through Ficoll-Hypaque". 
Monocytes were removed by adherence to plastic petri dishes at 37"C for 1 h. 
Informed consent 'was obtained in all cases. Cells ,\-vere used after cryopreservation 
using a controlled-freezing apparatus (Planer Biomed, Sunbury-on-Thames, UK). 
Generatioll of IL-7Ra alld G-CSF-R/IL7Ra expressioll cOllslmets. A 1.6 Kb EcoRI cDNA 
fragment (clone 20) in pBluescript (pBS), encoding full-length human lL-7Ra 
cDNA, was generously provided by Drs Steven Ziegler and Linda Park (Immunex 
Corp., Seattle, WA). The 1.6 Kb insert was cut out of pBS with EcoRI, bltmted, and 
ligated into the retroviral expression vector pLNCX, after linearization with Hpa!. 
A chimeric receptor composed of the extracellular part of human G-CSF-R and the 
transmembrane and intracellular parts of human IL-7Ra was made by recombinant 
PCR methods essentially as described by Skoda et al". First, sequences encoding 
nucleotides 129-1675 of the extracellular domain of G-CSF-R were amplified from 
G-CSF-R cDNA using forward primer GRFRI (CAAGATCACAAAGCTGGTGAA-
CATC) and reverse primer GRRV2 (GAAGATCCTCATAGAGCTGAAAG). The 
resulting product was cloned into the Hinell site of pBS and subsequently excized 
with Hind III and Bgll!. In the second PCR, the remainder of the extracellular 
domain of G-CSF-R (nucleotides 1663-2045) was amplified using forward primer 
GFFR2 (TGTGATCATCGTGACTCCCTT) that includes a Bcll site, and the chimeric 
G-CSFR/lL-7Ra primer GlL7RRV2 as reverse primer (GGTTAGTAAGATAGGGT-
GTAGCTCCGACCC). In the third PCR, sequences encoding the transmembrane 
and intracellular domains of lL-7Ra were amplified. Human lL-7Ra cDNA was 
amplified using the following primers: the chimeric G-CSF-R/lL-7Ra primer 
GlL7RFR2(GGGTCGGAGCTACACCCTATCTTACTAACC) and lL7RRV3 (TTGT-
CGCTCACGGTAAGTTCA). The fourth PCR, with primers GRFR2 and IL7RRV3, 
served to join the PCR products of PCR 2 and 3. The latter PCR product was ligated 
into the Hi ncIl site of pBS and then cut out with Bcll and Cia!' Finally, the PCR 
products of the first PCR (HindIII-BglII fragment) and of the fourth PCR (Bcll-Clal 
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fragment) were triple ligated into pLNCX (HindIIl - ClaI). The resulting product 
was subjected to nucleotide sequencing to verify in frame ligation of the G-CSF-R 
and IL-7Ra sequences. 
Gelleratioll of stable BAF3 trallsfectallts. The BAF3 cells were maintained in RPMI 
1640 medium (Gibco-BRL, Gaithersburg, MD) supplemented with 10% (v Iv) fetal 
calf serum (FCS) and an optimal concentration of chinese hamster ovary (CHO) 
cell-derived recombinant murine IL-3 (provided by Dr. J.N. !hIe, Memphis, TN). 
pLNCX vectors containing either the full-length IL-7Ra or G-CSF-R/IL-7Ra cDNA 
were transfected into BAF3 murine pro B cells by electroporation". Stably-
transfected clones expressing G-CSF-R/IL-7Ra were first selected on the basis of 
G418 resistance (1 mg/mL, Gibco-BRL). Subsequently, flow cytometric analysis 
(FACScan, Becton-Dickinson, Sunnyvale, CAl with antibodies against the 
extracellular domain of human G-CSF-R" was performed to determine the expres-
sion of the chimeric receptor proteins on the cell membrane. BAF3 transfectants 
expressing IL-7Ra were selected for their response to IL-7 in RPMI 1640 medium 
supplemented with 10% FCS and 100 U/mL human IL-7. Expression of IL-7Ra on 
BAF3/IL-7Ra cells was verified by FACScan analysis using anti-human IL-7Ra 
monoclonal antibody M21 (Immunex Corp.). 
DNA sYllthesis and cell proliferatioll assays. DNA synthesis was assayed by 'H-
thymidine ('H-TdR) uptake. Cells (10') were incubated in triplicate in 100 flL of 
10% FCS-RPMI culture medium supplemented with titrated concentrations of 
human IL-7, human G-CSF or 10 ng/mL murine IL-3 in 96-well plates for 24 h. 
Twelve hours before cell harvest, 0.1 flC of 'H-TdR (2 Ci/mM; International 
Amersham, UK) was added to each well. Radioactivity was measured by liquid 
scintillation cow1ting. To quantify cell proliferation in suspension culture, 2.5 x 10' 
cells were incubated in 25-mL culture flasks in 5 mL culture medium 
supplemented with growth fadors at the indicated concentrations, or without 
factors. Viable cells were counted on the basis of trypan blue exclusion. 
JAKI alld JAK2 illll11111l0precipitatiolls. BAF3 parental cells and transfedants were 
deprived of serum and factors and incubated in RPMI 1640 medium for 4 hours at 
31'C. Then, 2xlO' cells were incubated for 10 minutes in 4 mL RPMI containing 10 
flM sodium orthovanadate (Na,VO,) either without factor, or with murine IL-3 (1 
flg/mL), human IL-7 (100 ng/mL) or human G-CSF (1 flg/mL). Reactions were 
stopped by the addition of ice-cold phosphate buffered saline (PBS) containing 100 
flM Na,VO,. Subsequently, the cells were centrifuged and lysed on ice by the 
addition of 500 flL lysis buffer (0.5% Triton X-100, 10% glycerol, 50 mM Tris HCI 
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pH 8.0, 200 mM NaCl, 50 mM NaF, 3 mg/mL aprotinin, 1 mg/mL leupeptin, 1 mN! 
Na,VO" 1 mM Pefabloc (Boehringer, Marlliheim, Germany). Cell lysates were 
cleared by centrifugation for 30 minutes at 10,000 x g and incubated overnight with 
anti-JAKI or anti-JAK2 antiserum (gifts from Dr. IN. Thle), followed by the 
addition of Protein A-Sepharose beads (Pharmacia, Uppsala, Sweden) for 1 hour at 
4"C. Loaded beads were washed five times with ice-cold lysis buffer. BOlmd 
proteins were released from the beads by boiling for 5 minutes in sample buffer 
(10% glycerol, 5% II mercaptoethanol, 3% SOS, 0.1 M Tris HCl pH 6.8, 0.01% 
bromphenolblue). After separation by SOS polyacrylamide gel electrophoresis 
(SOS-PAGE) on 7.5% gels, proteins were transferred to nitrocellulose membranes 
by electroblotting. The membranes were blocked for 1 hour at 31'C with 0.3% (v Iv) 
Tween-20 in Tris buffered saline (TBS), and incubated overnight at 4"C with anti-
phospho tyrosine antibody 4GI0 (Upstate Biotechnology lnc., Lake Placid, NY), 
followed by a 1 hour incubation at room temperature with rabbit-anti-mouse Ig 
coupled to horseradish peroxidase (RAM PO; OAKO A/S, Glostrup, Denmark). 
The proteins were visualized by enhanced chenlo1ulllinescence (EeL; DuPont, 
Boston, MA). Subsequently, membranes were stripped in 62.5 mM Tris HCI pH 6.7, 
100 mM ll-mercaptoethanol, and 2% SOS for 30 minutes at 50"C, incubated with 
anti-JAKI or anti-JAK2 antibody for 1 hour, followed by incubation in peroxidase-
conjugated swine-anti-rabbit Ig (SWARPO; OAKO A/S) and subjected to ECL. 
Preparatioll of IIlIclear extracts. Methods were essentially as described in reference 25. 
In short: BAF3 parental cells and transfectants were deprived of serum and growth 
factors for 4 hours. Cells were stimulated for 15 minutes in RPMI without factor or 
in the presence of murine IL-3 (1 flg/mL), human G-CSF (1 flg/mL) or human IL-7 
(100 ng/mL). Stimulation was terminated by the addition of ice-cold PBS 
containing 1 mM Na,VO, and 5 mM NaF. Cells (50xl0') were lysed in 250 flL 
hypotonic buffer (20 mM Hepes, 20 mM NaF, 1 mM Na,VO" 1 mM Na,P,o" 0.125-
ftM okadaic acid, 1 mM EOTA, 1 mM EGTA, 0.2 % Nonidet P-40, 1 mM OTT, 0.5 
flg/mL aprotinin, 0.5 flg/mL leupeptin, 0.5 flg/mL bacitracin, 0.5 flg/mL 
iodoacetamide, and 1 mM Pefabloc). Nuclei were spun down at 15,000 g for 30 
seconds and proteins were extracted by rocking incubation for 30 minutes at 4"C in 
75 flL high-salt buffer (hypotonic buffer with 420 mM NaCl, and 20% glycerol). 
Insoluble materials were removed by tentrifugation at 20,000 g at 4°C for 20 
minutes. 
Nuclear extracts of BCP-ALL cells were prepared from cryopreserved bone 
marrow or blood samples. First, cells were cultured for 15 hours in serum free 
medium (10% BSA, 80 mg/mL transferrine, 20 ng/mL sodium-selenite, 2.2 mg/mL 
linoleic acid, 2.8 mg/mL cholesterol, 7 fJL/mL ll-mercaptoethanol, and 10 U /mL 
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insulin). Cells (5x106) were then incubated for 15 minutes in serum free medium 
with human IL-3 (100 ng/mL), with human IL-7 (100 ng/mI), or without factor. 
Stimulation was stopped by adding ice-cold PBS containing 5 mM NaF and 1 mM 
Na,VO,. Nuclear extracts were prepared as described above for BAF3 cells and 
transfectants except that the volumina were adapted for lower cell numbers. 
Gel retordotioll assays with STAT billdillg' oligollllcleotides. Nuclear extracts were 
incubated with double stranded g-32A TP end-labeled m67 oligonucleotides 
(5'CATTTCCCGTAAATC3')26 or ll-casein oligonucleotides (5'AGATTTCTAGGAA 
TTCAATCC3')27. It has been shown previously that m67 interacts with STAT 1 and 
STAT328, whereas the ll-casein probe specifically binds STAT529. Binding 
reactions were perfonned for 30 min at room temperature in 20 mL reaction 
volume containing 3 mL nuclear extract, 1 mL dIdC (2 mg/mL), 11 mL H20, 4 ml5 
x binding buffer (50 mM Hepes pH 7.6-7.8, 85 mM NaCi, 15 mM NaMo04, 4.25 
mM OTT, and 25% glycerol)17 and 1 mL labeled double stranded oligonucleotides 
(10.2 ng/mL). The reaction mixtures were fractionated by electrophoresis on 5% 
polyacrylamide gels. In supershift experiments, 2 mL of either anti-STATl, anti-
ST A T3 (Santa Cruz Biotecimology Inc., Santa Cruz, CAl or 1 mL anti-STA T5 
antibodies (provided by Dr. B. Groner, Freiburg, Germany) were added to the 
reaction mixture and incubated for 1 hour on ice} before the addition of the 
radiolabeled oligonucleotides. 
4.3 Results 
IL-7-illdllced activation of STAT complexes in Bep-ALL cells. Activation of STATs was 
analyzed in hwnan BCP-ALL cells from 13 patients. The series included 5 cases in 
which a proliferative response to IL-7 was observed in 'H-TdR uptake assays, and 8 
cases in which IL-7 failed to increase DNA synthesis. In gel retardation experi-
ments using m67 oligonucleotides, IL-7 induced a single DNA-binding complex in 
all cases (Fig. la, Table 1). Supershift assays with anti-STAT 1 antibodies demon-
strated that this complex contains STATl (Fig. lb). Binding of STAT3 to m67 was 
not detected. Gel shifts with STAT5- binding ll-casein oligonucleotides showed that 
IL-7 induced the formation of a single DNA-binding complex (Fig. 2a). 
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Figure 1 a) Gel retardation analysis of IL-7-induced protein binding to ~2P-labeled m67 oligo-
nucleotides in nuclear extracts from 4 BCP-ALL patients (PTI-PT4). After serum and growth factor 
deprivation, cells were stimulated without factor(w) or with human IL-7; b) Supershift assay of patient <1 
showing that the IL-7-induced STAT/m67 complex contains STAT! but not STAT3. The upper arrow 
indicates the position of the supershifted STAT1/m67 complex (lane 2). 
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Figure 2 a) Gel retardation analysis of IL-7-induced protein binding to nP-labeled B-casein 
oligonucleotides in nuclear extracts from 4 BCP-ALL patients (PTl-PT,!). After serum and growth factor 
deprivation" cells were stimulated without factor (-) or with human IL-7; b) Supershift assay of patient 4 
showing that the IL-7-induced STAT/B-casein complex contains STATS. TIle upper arrow indicates the 
position of the supershrfted STATS/B-casein complex (lane 4). 
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As expected, this complex could be supershifted with anti-STAT5, but not with 
anti-STATl or anti-STAT3 antibodies (Fig. 2b). IL-7 activated STAT5 in all BCP-
ALL cases (n=5) in which a proliferative response to IL-7 was observed, and in 4 of 
the 8 cases that failed to respond to IL-7 in DNA synthesis assays (Table 1). 
Table 1 IL·7-induced STAT activation in BCP·ALL cells 
BCP-ALL Immunologic IL-7 response STATI 
patient no. subtype (DNA·synthesis activation 
assay) induced by IL-7' 
1 common ALL no + 
2 null ALL yes + 
3 common ALL yes + 
4 common ALL yes + 
5 common ALL no + 
6 common ALL no + 
7 pre.BALL no + 
8 pre-BALL no + 
9. common ALL no + 
10 common ALL no + 
11 pre-B ALL no + 
12 common ALL yes + 
13 common ALL yes + 
determined by gel retardation assays using m67 oligonucleotides. 
determined by gel retardation assays using B-casein oligonucleotides. 
STAT5 
activation 
induced by IL·7' 
+ 
+ 
+ 
+ 
-
-
-
+ 
+ 
+ 
-
+ 
+ 
Proliferative respollses oj BAF3/IL-7R alld BAF3/Ch trallsjecfallts to [L-7 alld G-CSF. 
First, the abilities of IL-7Ra and chimeric G-CSF-R/IL-7Ra to transduce prolife-
rative signals in BAF3 cells were studied in 'H-TdR uptake assays (Fig. 3). 
BAF3/IL-7R cells responded to IL-7 (but not to G-CSF) in a dose dependent 
fashion. Plateau stimulation was reached at concentrations between 100 and 200 
ng/mL IL-7. Conversely, BAF3/Ch cells showed a dose dependent response to 
G-CSF, which reached a plateau at 20-50 ng/mL, but completely lacked 
responsiveness to IL-7. BAF3 parental cells did neither respond to IL-7 nor to 
G-CSF. Subsequently, proliferative responses were studied in suspension cultures. 
BAF3 parental cells died within four days in cultures containing either IL-7 or 
G-CSF (Fig. 4a). In contrast, BAF3/IL-7R and BAF3/Ch cells survived and 
proliferated continuously at optimal concentrations of IL-7 and G·CSF, respectively 
(Fig. 4b and c). 
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Figure 3 lH-TdR uptake in BAF3 parental cells BAF3/Ch and BAF3/IL-7R transfectants in response 
to titrated concentrations of G-CSF or IL-7, respectively. Data are expressed as percentages of maximal 
stimulation obtained with murine IL-3 for the individual cell clones. Data of BAF3 parental cells are 
from G-CSF supplemented cultures. Additional control incubations (BAP3 + JL-7i BAF3/Ch + IL-7i 
BAF3/IL-7R + G-CSF) did not result in increases of1H-TdR uptake over base-line levels (not shown). 
Aetivatioll of STAT eOlllplexes ill BAF3 trallsfeetallts. Irnmunoprecipitations with anti-
JAKI and anti-JAK2 antibodies on cell lysates from BAF3/IL-7R and BAF3/Ch 
cells are shown in Fig. 5 and Fig. 6. These experiments demonstrate that JAKI is 
tyrosine-phosphorylated upon stimulation of BAF3/IL-7R cells with IL-7. In 
contrast, IL-7 failed to activate JAK2 in these cells. Similarly, stinwlation of 
BAF /Ch cells with G-CSF results in the phosphorylation of JAKI but not JAK2. 
Stimulation of the cells with IL-3 induced phosphorylation of JAKI as well as 
JAK2. Taken together, these findings indicate that the cytoplasmic domain of 
IL-7Ra is capable of activation of JAKI (but not JAK2) without the involvement of 
the y, chain. 
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Figure 5 JAKI 
immunoprecipitation in 
BAF3 parental cells and 
BAF3/lL·7R and BAF3/Ch 
transfectants. Serum· and 
growth factor-deprived cells 
were incubated without 
factor (-), with murine JL-3, 
with human G-CSF (G) or 
with human IL-7. Upper 
panel: Blot stained with anti-
phosphotyrosine antibody 
4GIO. Lower panel: Same 
blot was stripped and repro-
bed with anti-JAKl antibo-
dies to confirm equal 
loading of JAKI proteins. 
Figllre 6 JAK2 
immunoprecipitation in 
BAF3 parental cells and 
transfectants. For details 
of incubation see Fig. 5. 
Upper panel: Blot stained 
with antibody 4G10. 
Lower panel: Same blot 
was stripped and repro-
bed with anti-JAK2 
antibodies to confirm 
equal loading of JAK2 
proteins. 
Activatioll of STAT complexes ill BAF3 trallsfectallts. In gel retardation assays with 
m67 oligonucleotides, three complexes were visible upon stimulation of the BAF3 
transfectants with IL-3 (Fig. 7a). These retarded complexes have previously been 
identified as STATl homodimers, STATljSTAT3 heterodimers and STAT3 
homodimers30, from bottom to top of the gel. Surprisingly, in view of the 
observations in Bep-ALL cells, lL-7 consistently failed to induce detectable binding 
of STATs to m67 oligonucleotides in BAF3jIL·7R cells. Even a 10 fold increase of 
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the concentration of IL-7 failed to induce STAT /m67 binding in BAF3/IL-7R cells. 
In contrast, activation of the chimeric G-CSF-R/IL-7Ra resulted in the formation of 
the three m67-binding complexes, although only marginal amounts of STAT3 
homodimeric complexes were detected. Supershift assays confirmed that the 
retarded bands consisted of STATl homodimeric, STATl/STAT3 heterodimeric 
and STAT3 homodimeric complexes (Fig. 7b). Gel retardation experiments with fl-
casein oligonucleotides showed that both IL-3 and IL-7 stimulation of BAF3 cells 
expressing the human IL-7Ra or the chimeric receptor induced DNA-binding 
activity with the double stranded fl-casein oligonucleotide. Supershift assays using 
anti-STA T5 antibodies demonstrated that this complex contains STAT5 (Fig. 8). 
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Figure 7 A Gel retardation analysis 
(a) and supershift assays (b) with 0167 
oligonucleotides in BAF3 cells and 
transfectantsi In the supershift assay 
anti-STAT! and anti-STAT3 antibodies 
were used to detect STAT /0167 
complexes in G-CSF-induced BAF3 
transfectants. Antibodies against 
STATS and Tyk2 were included as 
controls. 
Figure 7b 
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Figure 8 Gel retardation and supershift analysis with B-casein probe in BAF3 cells and transfectants. 
Supershift analysis demonstrated that the STAT /B-casein complexes contain STAT5 (lane 6; 8, II, and 
13). The upper arrow indicates the position of the supershifted STATS/B-casein complex. 
4.4 Discussion 
In this study, we have demonstrated that IL·7 induces the activation of STATl and 
STAT5 in BCp·ALL cells. In most patients, BCP·ALL cells express IL·7Ra and y, 
chains'. Yet, IL·7 induces a proillerative response in BCp·ALL cells in about half of 
the patients only'''. Currently, there is no explanation for this heterogeneous 
response pattern. In normal B cell precursors, the ability of IL·7 to induce a full 
mitogenic signal correlates with the rearrangement and expression of the immw10· 
globulin heavy and light chain (precursor) genes". In contrast, IL·7 responsiveness 
of BCP-ALL cells does not depend on the inm1W1oglobulin gene status'. IL-7 
activated STATl and STAT5 in all BCP-ALL cases that respond to IL-7 in proille-
ration assays. However, IL·7 also induced STAT activation in BCP-ALL cases that 
failed to proliferate in response to IL-7. Thus, activation of STATs appears not 
sufficient for evoking a mitogenic response in BCP-ALL cells. 
IL-2, IL·4, IL-7, IL-13, and IL-l5 have overlapping as well as distinct effects on 
peripheral blood lymphocytes (PBL). Two patterns of STAT activation by these 
cytokines in PBL have recently been recognized: IL-4 and IL-l3 activate a STAT 
protein known as IL-4NAF, STF-IL-4 and IL-4 STAT, whereas IL-2, IL-7 and IL-l5 
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activate STAT3 and STATS but not STATl'". Our findings indicate that the latter 
pattern cmmot simply be extrapolated to other cell types, since in BCP-ALL cells 
IL-7 activated STATl (all cases), STATS (most cases) but never STAT3. The reasons 
for these discrepancies are unknown, but could relate to differential expression of 
STATs and/or docking molecules involved in the recruitment of STAT proteins to 
the IL-7R complex. Studies of Kawahara et aJ. suggested that the cytoplasmic 
region of the y, chain is crucial for IL-7-induced proliferative signaling in F7 cell 
transfectantsw• Whether the cytoplasmic domain of IL-7Ra is also required for 
growth signaling was not investigated in this study. Our experiments with BAF3 
transfectants expressing chimeric G-CSF-R/IL-7Ra proteins (BAF3/Ch) indicate 
that signaling substrates activated via the cytoplasnlic domain of IL-7Ra are also 
fully capable of inducing STAT activation and transducing growth responses. 
Again, this does not imply that STATs are essential for proliferative signaling and 
some experiments even directly argue against such a role of STA Ts. For instance, it 
was recently demonstrated that the cytoplasmic region of the IL-2R required for the 
activation of STATS is not essential for IL-2-induced cell proliferation". Several 
other candidate signaling substrates that could play a role in IL-7-induced 
proliferative signaling have been identified. The src-like protein tyrosine kinases 
pS9'"' and pS3/sd'" and the p8S subunit of Pl3-kinase are activated by IL-7. 
Association of pS3/S6f~' and the p8S subunit of Pl3-kinase wiith the IL-7R complex 
occurs via (phospho-) tyrosine-containing domains located in the membrane-distal 
cytoplasmic region of the IL-7Ra chain, while pS9'~' is associated with the 
cytoplasmiC tail in a phosphotyrosine independent way""'. In view of this, it is 
noteworthy that tnmcated IL-7Ra or G-CSF-R/IL-7Ra proteins, that lack this 
membrane-distal cytoplasmic region, completely fail to transduce proliferation 
signals in BAF3 cell transfectants (Smiers etal, submitted). 
We consistently observed that STATl- and STAT3-containing complexes were 
activated by G-CSF in BAF3/Ch cells. In contrast, such complexes were not 
detected in IL-7-stimulated BAF3/IL-7R cells, although IL-7 activated JAKl and 
STATS, and induced proliferation at levels comparable to those induced by G-CSF 
in BAF3/Ch cells. We cannot explain this discrepancy. One possibility is that 
activation of STATl- and STAT3- containing complexes in the BAF3/IL-7R cells is 
hampered because complex formation of human IL-7Ra and murine y, is limited. 
This may be due to the very 100w expression of the Yc chaiIl lO, vvhich ,vould 
predictively result in the low activation of JAK3. In agreement with this, we were 
unable to detect IL-7-induced JAK3 activation in the BAF3/IL-7R cells (data not 
shown). An alternative more complex hypothesis is based on the assumption that 
the chimeric G-CSF-R/IL-7Ra complexes activated by G-CSF contain other 
unknown receptor structures that bind to the G-CSF-R extracellular domain, in 
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analogy to what has been suggested for the erythropoietin (EPG) receptor". In 
theory, such an unknown receptor component could then be involved in signaling 
and, e.g., activate STATl- and STAT3- containing complexes in the BAF3/Ch cells. 
However, the heteronleric EPO-R luodel has remained controversial36, and for G-
CSF-R no evidence supporting the existence of additional receptor chains has been 
put forward at all. 
In sunmlary, our results have established that IL-7 activates STATI and STAT5 in 
leukemic B cell precursors via the cytoplasmic domain of the IL-7Ra chain but 
suggest that signaling molecules other than STATs, activated via this receptor 
donlain, are essential for transducing gro,vth signals in these cells. The role of 
STATs in IL-7- mediated responses in normal and leukemic B cell precursors 
remains to be established. 
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Abstract 
Interleukin (IL-) 7 activates a receptor complex that consists of a specific IL-7Ra 
chain and a common y chain (y) shared with the receptors for IL-2, IL-4, IL-9, IL-13 
and IL-lS.To study which regions in the IL-7Ra are crucial for signaling, we 
constructed receptor chimeras (Ch) composed of the extracellular domain of the 
human G-CSF-R and the cytoplasmic domain of human IL-7Ra (ChI and Ch2) or 
mouse IL-7Ra (Ch3 and Ch4). The transmembrane (TM) domain was either from 
G-CSF-R (ChI and Ch3) or IL-7Ra (Ch2 and CM). We show that activation of Ch2 
and Ch4, induced by G-CSF, induces sustained proliferation of BAF3 transfectants, 
whereas activation of ChI and Ch3 failed to do so, indicating that the IL-7Ra TM 
donlain is of crucial inlportance for proliferation induction by the chimeric 
receptors. We then compared the signal transduction abilities of ChI and Ch2. 
Whereas Ch2 activates substrates of the JAK/STAT pathway (JAKI/STATS), the 
p21Ras signaling route (SHP-2, ERKl, ERK2) and the PI-3 kinase pathway (p8S and 
lRS-2), none of these substrates was activated by ChI, with the notable exception of 
STATS. C-terminal truncation of 111 amino acids of Ch2, removing three conserved 
tyrosines of the cytoplasmic domain, also completely disrupted mitogenic signaling 
by this chimera. These findings indicate that both the TM domain and the C-
terminal region of IL-7Ra playa critical role in signaling and suggest that STATS 
may be activated by IL-7Ra via mechanisms not involving JAKs. 
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5.1 Introduction 
Interleukin (IL-) 7, secreted by stromal cells in the bone marrow and thymus, has 
profound proliferation inducing effects in both the Band T lymphoid lineages "'. 
These effects are mediated via a heteromeric receptor complex that consists of an 
IL-7 specific a chain' and a common Y (y,) chain, which is shared by the receptors 
for IL-2, IL-4, IL-7, IL-9, IL-13 and IL-15 "'. Both the a and y chains of the IL-7R 
complex contribute to IL-7-induced intracellular signaling '''. Recently a number of 
signaling molecules activated by IL-7R have been identified. These include the JAK 
kinases JAKI and JAK3, STAT (signal transducer and activator of transciption) 1 
and STAT5, ERKI and ERK2, phosphatidyl inositol-3 kinase (PI-3K) and the insulin 
responsive substrate (IRS) 1 and IRS2 n.". It is not yet clear how these molecules are 
activated by the IL-7R complex. 
In the present study, we investigated the signaling flulction of chinle ric receptors 
containing the extracellular domain of human G-CSF-R and the cytoplasmic 
domains of human IL-7Ra. Upon activation with G-CSF, these chimeric G-CSF-
R/IL-7Ra do not recruit the Yc chain into the receptor complex, and thus provide 
tools for studying the specific contribution of the IL-7Ra to IL-7-mediated cellular 
responses. We show that G-CSF-R/IL-7Ra chimeras are in principle fully capable 
of activating intracellular nlechanisms controlling· proliferation, suggesting that the 
comnlon y chain is not absolutely required for the transduction of lnitogenic signals 
from IL-7R. In addition, we provide evidence to suggest that the TM domain of 
IL-7Ra plays a crucial role in IL-7R function. Finally, we show that mitogenic 
signaling by IL-7Ra is fully dependent on the presence of the membrane distal 
cytoplasmic region of the receptor. This is in marked contrast to other members of 
the cytokine receptor family, for instance G-CSF-R, EPO-R, gp130 and the common 
f3 chain of GM-CSF/IL-3/IL-5 receptors, of which it has been shown that the 
nlenlbrane proximal region, containing the conserved box1 and box2 sequences, is 
necessary and sufficient for inducing proliferation in BAF3 cells. 
5.2 Materials and Methods 
Gelleratioll of IL-7Ra alld G-CSF-R/IL-7Raexpressioll COllstmets 
A schematic representation of the receptor constructs is shown in Fig. 1. Four 
different chimeric receptors composed of the extracellular part of human G-CSF-R, 
the G-CSF-R transmembrane region (chimera 1 and 3), human- or murine IL-7Ra 
transmembrane region (respectively chimeras 2 and 4), and the intracellular parts 
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of the human- or murine IL-7Ra chain (respectively chimeras 1 and 2 and 
chimeras 3 and 4) were made by recombinant PCR methods essentially as descri-
bed by Skoda et al '" and reported for Ch2 in detail in ". First, sequences encoding 
nucleotides 129-1675 of the extracellular domain of G-CSF-R were amplified from 
G-CSF-R eDNA using forward primer GRFR1 (CAAGATCACAAAGCTGGTGAA-
CATC) and reverse prinler GRRV2 (GAAGATCCTCATAGAGCTGAAAG). The 
resulting product was cloned into the Hine II site of pBS and subsequently excised 
with Hind III and Bgi II. 
extracellular TM extracellular 
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Figure 1 Schematic representation of receptor constmcts. TM: transmembrane domain. rUII: HindlII 
restriction site. hIL-7R and mIL-7R: wild type human and murine IL-7Ra chain; hIL-7R-T: tnmcated 
human IL-7Ra mutant; hG-CSF-R: wild type hG-CSF-R; Chl-4: chimeric G-CSF-R/lL-7Ra receptors as 
used in these experiments; Ch2-T: truncated form of Ch2. The indicated positions of the tyrosine (Y) 
residues is according to the nomenclature of Goodwin et al. 1. 
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In the second PCR, the remainder of the extracellular domain of G-CSF-R (nucleoti-
des 1663-2045) was amplified using forward primer GRFR2 (TGTGA-
TCATCGTGACTCCCTT) that includes a Bcl I site, and the reversed primers GIL-
7RVI (AGGCTTAATCCTTTTTTTGTTGGGGCTGCAACA) for chimeras 1 and 3, 
GIL7RRV2 (GGTTAGTAAGATAGGGTGTAGCTCCGACCC) for chimera 2, and 
GIL-7RRV3 (ACTTGGCAAGACAGGGTGTAGCTCCGACCC) for chimera 4. 
In the third PCR, sequences encoding the different transmembrane and intracellu-
lar domains of human or murine IL-7Ra were amplified. Human IL-7Ra cDNA was 
amplified using the following primers: GIL-7RFRI (TGTTGCAGCCCCA 
ACAAAAAAAGGATTAAGCCT) with IL-7RRV3 (TTGTCCTCACGGTAA 
GTTCA) for chimera 1 and with IL-7RRVI (TTGTCGCTCACGTAGTCA) for 
chimera 3, GIL-7RFR2 (GGGTCGGAGCTACACCCTATCTTACTAACC) and 
IL-7RRV3 for chimera 2, and GIL-7RFR3 (GGGTCGGAGCTACACCCTGTCTTG 
CAAGT) with mIL-7RRVl (TTGGTTGTCGATGGAAGGG) for chimera 4. 
The fourth PCR, with primers GRFR2 and IL-7RRV3 (chimeras 1 and 2) and GRFR2 
and IL-7RRVI (chimeras 3 and 4) served to join the PCR products of PCR 2 and 3. 
The latter PCR product was ligated into the Hinc II site of pBS and then cut out 
with Bcl I and CIa I. Finally, the PCR products of the first PCR (Hind III-BgI II frag-
ment) and of the fourth PCR (Bcll-Clal fragment) were triple ligated into pLNCX 
(Hind III - CIa I). The resulting products were all subjected to nucleotide sequen-
cing to verify in frame ligation of the G-CSF-R and IL-7Ra sequences. To generate 
Ch2-T and IL-7R-T, the respective plasmids were digested with Hind III and 
religated, thereby removing the 111 C-terminal amino acids (See Fig. 1) For the 
construction of the truncated IL-7Ra and chimera 2 receptor the Hind III site in the 
cytoplasmic part of the IL-7Ra chain was used. The resulting trwlcated receptor 
does no longer contain tyrosine residues. 
Generafioll oj sfable BAF3 frallsjecfallfs 
Interleukin-3 dependent BAF3 cells were maintained in culture medium consisting 
of RPMI 1640 medium (Gibco-BRL, Gaithersburg, MD) supplemented with 10% 
(v /v) fetal calf serum (FCS) and Chinese hamster ovary (CHO) cell-derived 
recombinant murine IL-3 (kindly provided by Dr. J.N. !hIe, Memphis, TN). These 
cells were fully dependent on IL-3 and died within 18 hrs in the absence of growth 
factor, or in the presence of IL-7 or G-CSF. Expression constructs were transfected 
into BAF3 cells by electroporation 31. Stably-transfected clones expressing G-CSF-
R/IL-7Ra were first selected on the basis of G418 resistance (1 mg/mL, Gibco-
BRL). Subsequently, flow cytometric analysis (FACScan, Becton-Dickinson, 
Sunnyvale, CAl with antibodies against the extracellular domain of human G-CSF-
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R" was performed to determine the expression of the chimeric receptor proteins on 
the cell membrane. BAF3 transfectants expressing IL-7Ra were selected for their 
response to IL-7 in RFMI 1640 medium supplemented with 10% FCS and 100 
U/mL human IL-7. Expression of IL-7Ra on BAF3/IL-7Ra cells was verified by 
FACScan analysis using anti-human IL-7Ra monoclonal antibody M21 (Immunex 
Corp.). 
DNA synthesis and proliferation assays 
DNA synthesis was measured in JH-thymidine ('H-TdR) uptake assays. Cells (10') 
were incubated in triplicate in 100 J.lL of RFMI-10% FCS supplemented with 
titrated concentrations of human IL-7, human G-CSF or 10 ng/mL murine IL-3 in 
96-well plates for 24 h. Twelve hours before cell harvest, 0.1 J.lC of 'H-TdR (2 
Ci/mM; International Amersham, UK) was added to each well. Radioactivity was 
measured by liquid scintillation counting. To quantify cell proliferation in 
suspension culture, 2.5 x 10' cells were incubated in 25-mL culture flasks in 5 mL 
culture medium supplemented with growth factors at the indicated concentrations, 
or without factors. Viable cells were counted on the basis of trypan blue exclusion. 
llIIlIIlIllOprecipitation and WesteYll blotting 
BAF3 parental cells and transfectants were deprived of serum and factors by 
incubation in RFMI for 4 hours at 37 'c. Then, 2x10' cells were incubated for 10 
minutes in 4 mL RFMI containing 10 ItM sodium orthovanadate (Na,VO,) either 
without factor, or with murine IL-3 (1 J.lg/mL), human IL-7 (100 ng/mL), human 
G-CSF (1 Itg/mL) or insulin (10 J.lg/ml). Reactions were stopped by addition of ice-
cold phosphate buffered saline (PBS) containing 100 J.lM NaJVO,. For JAK1 
ummmoprecipitations, cells were centrifuged and lysed on ice by the addition of 
500 J.lL lysis buffer (0.5% Triton X-100, 10% glycerol, 50 mM Tris HCl pH 8.0, 200 
mM NaCi, 50 mM NaFcontaining a cocktail of protease inhibitors (3 mg/mL 
aprotinul, 1 mg/mL leupeptin, 1 mM NaJVO" 1 mM Pefabloc; Boehringer, Mann-
heinl, Germany). Celllysates were then cleared by centrifugation for 30 minutes at 
10,000 x g and ulcubated overnight at 4 "C with anti-JAK1 antiserum (a gift from 
Dr. J.N. TIlle). For Grb2 and p85/PI3K unmunoprecipitations, cells were lysed in a 
buffer containing 20 mmol/L Tris (pH 8.0),137 mmol/L NaCi, 10 mmol/L EDTA, 
100 mmol/L NaF, 1% Nonidet P-40, 1 mmol/L OTT, 10% glycerol, 2 mmol/L 
NaJVO" and 8the cocktail of protease inhibitors mentioned above. Lysates were 
incubated overnight at 4'C with anti- Grb2 (Santa Cruz Biotechnology Inc.,Santa 
Cruz, CAl or polyclonal anti-p85PI-3K ". Immune complexes were coupled to Pro-
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tein A-Sepharose beads (Pharmacia, Uppsala, Sweden) by incubation for 1 hour at 
4'C and washed five tinles with ice-cold lysis buffer. Bound proteins were released 
from the beads by boiling for 5 min in sample buffer (10% glycerol, 5% 1l 
mercaptoethanol, 3% SDS, 0.1 M Tris HCl pH 6.S, 0.01% bromphenolblue). After 
separation by SDS polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5% gels, 
proteins were transferred to nitrocellulose membranes by electroblotting. The 
membranes were blocked for 1 hour at 31'C with 0.3% (v Iv) Tween-20 in Tris 
buffered saline (TBS), and incubated overnight at 4'C with anti-phosphotyrosine 
antibody 4G10 (Upstate Bioteclmology Inc., Lake Placid, NY), followed by a 1 hour 
incubation at room temperature with rabbit-anti-mouse Ig coupled to horseradish 
peroxidase (RAMPO; DAKO A/S, Glostrup, Denmark). The proteins were 
visualized by enhanced chemoluminescence (ECL; DuPont, Boston, MA). 
Subsequently, membranes were stripped in 62.5 mM Tris HCl pH 6.7, 100 mM 1l-
mercaptoethanol, and 2% SDS for 30 minutes at 50'C, incubated with anti-JAK1 an-
tibody, for 1 hour, followed by incubation in peroxidase-conjugated swine-anti-
rabbit Ig (SWARPO; DAKO A/S) and subjected to ECL. Whole cell lysates were 
subjected to Western blotting with anti Erkl/Erk2 antibodies (Santa Cruz) and ECL 
detection to investigate the activation of p42/p44 MAPK. The activated forms of 
p42/p44 are retarded in the gel and can be recognized as such. 
Preparatioll of IlIlclear extmcts 
Nuclear extracts were prepared as described". In short: BAF3 parental cells and 
transfectants were deprived of serum and growth factors for 4 hours. Cells were 
stinllllated for 15 minutes in RPMI without factor or in the presence of murine IL-3 
(lllg/mL), human G-CSF (lllg/mL) or human IL-7 (100 ng/mL). Stimulation was 
terminated by the addition of ice-cold PBS containing 1 mM Na,VO, and 5 mM 
NaF. Cells (50x10') were lysed in 250 ilL hypotonic buffer (20 mM Hepes, 20 mM 
NaF, 1 mM Na,VO" 1 mM Na,P,o" 0.125 11M okadaic acid, 1 mM EDTA, 1 mM 
EGTA, 0.2 % Nonidet P-40, 1 mM OTT, 0.5 Ilg/mL aprotinin, 0.5 Ilg/mL leupeptin, 
0.5 Ilg/mL bacitracin, 0.5 Ilg/mL iodoacetamide, and 1 mM Pefabloc). Nuclei were 
spun down at 15,000 g for 30 seconds and proteins were extracted by rocking 
incubation for 30 minutes at 4'C in 75 IlL high-salt buffer (hypotonic buffer with 
420 mM NaCl, and 20% glycerol). Insoluble materials were removed by centrifu-
gation at 20,000 g at 4'C for 20 minutes. 
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Electrophoretic mobility shift assays (EMSA) with STAT binding oligonllcleotides 
Nuclear extracts were incubated with double stranded y-"ATP end-labeled Jl-casein 
oligonucleotides (5'AGATTTCTAGGAATTCAATCC3'j". It has been shown 
previously that the fl-casein probe specifically binds STAT5 os. Binding reactions 
were performed for 30 Inin at room temperature in 20 pL reaction volume con-
taining 3 [lL nuclear extract, 1 [lL dIdC (2 [lg/mL), 11 flL H,o, 4 fl15 x binding 
buffer (50 mM Hepes pH 7.6-7.8, 85 mM NaC!, 15 mM NaMoO" 4.25 mM DTT, 
and 25% glycerol)" and 1 [lL labeled double stranded oligonucleotides (10.2 ng/[l-
L). The reaction mixtures were fractionated by electrophoresis on 5% polyacryl-
mnide gels. 
Results and discussion 
Proliferation sigllaling ill BAF3 tralls/ectallts 
First, the proliferative responses of BAF3 transfectants, ectopically expressing 
IL-7Ra or chimeric G-CSF-R/IL-7Ra proteins, to titrated concentrations of IL-7 of 
or G-CSF were measured using 'H-TdR uptake assays. BAF/hIL-7Ra and 
BAF/mIL-7Ra both responded maximally to, respectively, human and murine IL-7 
at concentrations of 10 ng/ml (Fig. 2a). Similarly, BAF /Ch2 and BAF /Ch4 cells 
responded to G-CSF in a dose dependent fashion (Fig 2b). In contrast, the 
C-terminal truncation mutants of hIL-7Ra (hIL-7R-T) and Ch2 (Ch2-T) completely 
failed to transduce proliferative signals (Fig. 2 a,b), indicating that mitogenic 
signaling from IL-7Ra requires the presence of the C-terminal cytoplasmic region 
of the protein. Strikingly, in view of the fact that they comprised the entire IL-7Ra 
cytoplasmic domain, ChI and Ch3 were also completely unable to deliver 
proliferative signals, even at a concentration of 100 ng/ml of G-CSF (Fig 2b). Thus, 
the TM domain of IL-7Ra plays a crucial role in the signaling ftmction of the 
G-CSF-R/IL7Ra chimeras. 
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Tile IL-7Ra TM domaill is required for activatioll of JAKl, p85(PI-3K), ERKI/ERK2 alld 
SHP-2 
Next, we compared the abilities of ChI and Ch2 to activate signaling molecules 
known to be involved in IL-7-mediated cellular responses. Immunoprecipitations 
with anti-JAKI followed by Western blot analysis using anti-phospho tyrosine 
antibodies indicated that JAKI is activated by Ch2, but not to a detectable extent by 
ChI (Fig. 3). Immunoprecipitations with anti-Grb2 showed that, whereas activation 
of WT G-CSF-R and IL-3R, induces the formation of complexes of Grb2 with the 
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pS2 Shc and Grb2 with the p70 SHP-2, activation of Ch2 induced the formation of 
Grb2/SHP-2 but not Grb2/Shc complexes (Fig. 4) 37. The observation that Ch2 
induced ERKI/ERK2 activation without involvement of Shc is in agreement with 
data from Dorsch et aI., who showed that IL-7R does not activate Shc os. ChI failed 
to activate the formation of Grb2/SHP-2 complexes. From immunoprecipitations 
with anti-PI-3K (p8S) antibodies, it appeared that both insulin and IL-3 induced 
complex formation between p8S(PI-3K) and the 185 kD protein IRS-2. Co-
precipitation of IRS-2 with p8S was also seen upon activation of Ch2 or IL-7R, but 
not ChI (Fig.5). Similarly, whereas Ch2 activated ERKI and ERK2, ChI failed to do 
this completely (Fig. 6). 
JAK1-
BAF/Ch1 BAF/Ch2 
r-----'Ir-I -----.., 
IL3 G IL3 G M 
.. 
.... p, .••....... 
1;''' 'C', 'C 
Figure 3 JAKI immunoprecipitation in BAF jChl and BAF jCh2 cells. Serum- and growth factor 
deprived cells were incubated without factor H, with murine IL-3 or with hwnan G-CSF (G). The blot 
was stained with anti-phosphotyrosine antibody 4GIO. 
BAF/Chl BAF/G·CSF·R BAF/Ch2·5 BAF/Ch2·9 
Ii 
M IL3 G IL3 G IL3 G IL3 G 
-
. ·1 
-
Figure 4 Grb2 immunoprecipitation in BAF jChl and BAF jCh2 (clones 5 and 9). Blots were stained 
with anti*phosphotyrosine antibody 4GIO. Co*immunoprecipitating proteins Shc and SHP-2 are 
indicated by arrows. 
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Although little is known of possible regulatory functions of the transmembrane 
domain in signal transduction, a number of studies have indicated that alterations 
in the transmembrane domain may significantly affect the signaling function of 
growth factor receptors. For instance, a mutation in the transmembrane domain of 
the receptor encoded by the proto-oncogene neu results in the constitutive 
activation of its intrinsic tyrosine kinase activity'" "'. This mutated neu protein has 
altered dimerization properties, but these do not explain the constitutive activated 
state of the receptor, suggesting additional signaling properties of the 
transmembrane domain". Similarly, mutations in the transmembrane domain of 
the common Jl subunit of IL-3/IL-5/GM-CSF receptors renders these receptors 
constitutively active". Conversely, replacement of the transmembrane region of the 
PDGF receptor with those of other receptors abolished ligand induced activation of 
tyrosine kinase activity". Finally, EGFR/c-ros chimeric receptors, differing only in 
transmembrane domains, were fOlmd to have completely opposite signaling effects 
depending on the transmembrane domain ". Our data suggest that the TM domain 
of IL-7Ra has a function in signaling that cannot be replaced by the G-CSF-R TM 
domain. Which mechanisms are specifically influenced by this domain is not yet 
clear. It is possible that the IL-7Ra TM domain contributes to a conformation of the 
cytoplasmic domain essential for JAKl binding and activation. Alternatively, full 
mitogenic signaling from the IL-7R complex may depend on the formation of 
complexes involving muliple IL-7Ra chains and/or as yet unidentified proteins for 
which the integrity of the IL-7Ra TM domain is crucial. 
BAF/Chl BAF/Ch2 BAF/hlL7R 
_ p185/1RS-2 
Figure 5 ImnnUloprecipitation with anti-pBS (PI-3K). Senlffi- and growth factor deprived cells were 
incubated without factor H, insulin (Ins), IL-3 or human G-CSF (G). Western blotting was performed 
with anti-phosphotyrosine antibody 4GIO. 
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BAF/Ch1 
j I 
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Figure 6 Western blot analysis of activation ofERKl/ERK2 (p44/p42). Activated forms of Erkl/Erk2 
are retarded in the gel (marked by asterisks). 
STAT5 activatioll by G-CSF-R/IL-7Ra cllimeras flllly depellds all tile presellce of the 
IL-7RaC-terllliIllIS bllt does lIot reqllire the IL-7RaTM dOlllaill 
The abilities of the receptor mutants to activate STAT5 were analyzed by EMSA 
with j3-casein oligonucleotides ". As shown in Fig. 7, activation of STAT5 by IL-7R 
or Ch2 is completely abolished by truncation of the C-terminus (IL7R-T and Ch2-
T). Previously, it has been demonstrated that tyrosine residue (Y429) in the IL-7Ra 
C-terminus (Figl) is engaged in the docking of STAT5 to the receptor ". Our data 
suggest that recruitment of STAT5 to the IL-7Ra C-terminus, possibly, but perhaps 
not exclusively, via Y429, is a prerequisite for IL-7-induced activation of STAT5. 
Strikingly, in view of its inability to activate JAKI, ChI still induced STAT5 
activation, indicating that this chimeric protein is not a completely 'dead' receptor 
and suggesting that alternative mechanisms not involving JAKs might be involved 
in the activation of STAT5 mediated via the cytoplasmic domain of IL-7Ra. 
Because neither JAK2, JAK3 or Tyk2 are activated by IL-7Ra or ChI and Ch2 ( " 
and data not shown), these data suggest that STAT5 can be activated by IL-7Ra via 
mechanisms not involving JAKs. It has recently been established that other tyrosine 
kinases, for instance of the Src family, are also capable of tyrosine phosphorylation 
of STAT proteins "'''. Possibly, the Src-like kinase Fyn, which is constitutively 
associated to the IL-7Ra C-tenninus, is involved in IL-7-induced tyrosine phosho-
rylation of STAT5 ". 
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Figure 7 EMSA with p~casein probe on nuclear extracts of BAF3 cells expressing various IL-7Ra and 
chimeric G-CSF-R/IL-7R« forms. Cells were deprived of growth factors and serum for 4 hours and 
then incubated in serum free medium without factor (-), mIL-3 (1 JIg/mil, hGCSF (1 J1g/ml), or hIL-7 
(100 ~g/ml), 
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Summary 
Acute lymphoblastic leukemia (ALL) is a highly heterogeneous group of diseases. 
Recognition of factors that predict outcome permits the identification of patients 
with different risks and allows for the selection of treatment adjusted to risk. Some 
progress has been made in the understanding of the role of hematopoietic growth 
factors (HGFs) that control the proliferation and differentiation of normal and 
leukemic B- and T-cell progenitors (BCP and BTP). Interleukin 7 is an active growth 
factor for normal and leukemic precursor Band T cells. IL-4 may inhibit the 
proliferation of normal and leukemic BCP cells. Sometimes ALL cells show 
spontaneous proliferative activity in culture, independent of the addition of a 
gro\vth factor stimulus. 
Here we present the results of an analysis in which the predictive value of 
spontaneous and IL-4 or IL-7 induced DNA synthesis in vitro of ALL cells from 73 
patients was investigated with respect to clinical outcOIne. No significant relati-
onship was found 
between spontaneous or IL-7 induced or IL-4 mediated proliferation with clinical 
outcome. 
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6.1 Introduction 
Acute lymphoblastic leukemia (ALL) is a neoplastic disease with uncontrolled 
clonal expansion of immature lymphoblastic cells that have lost the capacity for 
terminal maturation. ALL is a heterogeneous disease and conlprises a group of 
conditions with distinct clinical, pathological, immunological and genetic features. 
Through the recognition of clinical and hematological risk factors one may adjust 
treatment to patients with different risks. For instance patient age, white blood cell 
COlmt (WBC) at diagnosis, inummophenotype and the presence of specific 
cytogenetic abnormalities of the leukemias express prognostic value and may 
deternline treahnent choice. 
In normal hematopoiesis hematopoietic growth factors participate in a regulating 
network that controls the expansion and development of hematopoietic stem cells 
towards blood cells of the various lineages. Distinct cell stages of nlaturation res-
pond to specific hematopoietic growth factors. Interleukin 7 (IL-7) is a bone 
marrow stronlal gl'O'wth factor that may activate nonnal and leukeulic hunlan B 
and T cell precursors (BCP and BTP) although in leukemic B cell precursor cells 
considerable heterogeneity of responsiveness has been observed (1,2). In normal B-
cell precursor cells IL-7 as single growth stimulus induces proliferation in the pre-
B cell stage only. In more inunature stages IL-7 synergizes with stromal factors. In 
mature B cells the response to IL-7 is lost (2). In leukemic BCP cells the mahlrati-
onal stage dependent response pattern no longer exists (2). 
IL-4 is a T cell derived growth factor that may potently inhibit the proliferation in 
normal and leukemic B-cell precursor cells (3,4). In mature B cells IL-4 induces 
proliferation in synergy with simultaneous B cell receptor activation or CD40 
activation. In (im)mature T cells IL-4 induces proliferation. 
Proliferation in the absence of exogenous added hematopoietic growth factors (i.e. 
spontaneous or autonomous proliferation) may be apparent in leukemia cell 
culture. Spontaneous proliferation in culture has been reported both in ALL and 
acute myeloid leukemia (AML). In AML the ability of spontaneous proliferation in 
culture has been demonstrated to correlate with clinical outcome (5). It is not 
known whether the level of spontaneous proliferation or IL-4 and IL-7 induced 
proliferation of leukemic cells cells express prognostic value in ALL. 
Here we present the results of a study in which in vitro proliferation parameters 
were related to clinical outcome in a series of pediatric and adult patients with 
ALL. 
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6.2 Methods 
PatieJlts alld treatmellt 
Marrow and blood specimens from 73 patients with pathologically and 
immlmologically confirmed ALL referred to the University Hospital Rotterdam 
(Daniel den Hoed Cancer Center or the Sophia Children's Hospital) between 1988 
and 1994, were analysed. 
Patients YOlmger than 15 years at time of diagnosis (n=43) have been treated 
according protocols of the Dutch Childhood Leukemia Study Group. Adult 
patients (n=30) have been treated according protocols HOVON-5 and HOVON-18 
of the Dutch Hemato-Oncology Cooperative Group. Median follow up for patients 
still alive is 40 months (range 9-122 months). Allogeneic bone marrow transplan-
tation has been performed in one pediatric and 6 adult patients in renlission. 
Autologous bone marrow reinfusion was done in one adult patient. 
Cell samplillg 
Cells were derived from the bone marrow or peripheral blood taken for diagnostic 
purposes following informed consent. All cell samples were isolated from bone 
marrow or peripheral blood by Ficoll-Hypaque (Nygaard,Oslo,Norway) density 
gradient centrifugation as described previously (6). 
T cells were removed from B cell precursor ALL samples by E-rosette formation 
using 2 aminoethylisothiouronium bromide (AET)-treated sheep red blood cells, 
followed by sedimentation through Ficoll Hypaque (7). Monocytes were removed 
by adherance to plastic petri dishes for 1 hour at 31' C. All BCP-ALL cell samples 
were subjected to routine diagnostic immlmopheno-typing. Leukemic cells were 
subclassified as null-ALL (CD10-, CD19+, CD34+, Cytoplasmic" -), common-ALL 
(CD10+, CD19+, CD34+/-, Cytoplasmic"-) or pre-B ALL (CD10+, CD19+, CD34+/-, 
Cytoplasmic,,+) (8). 
Cytogenetic analysis was perfofIned on bone nlarrmv aspirates and nl0st often also 
on periripheral blood, according standard techniques (9,10). Among 43 pediatric 
patients a t(9;22) was observed in 2 patients, a t(1;19) in 2 patients and translocati-
ons involving llq23 in 5 patients. In 20 patients other cytogenetic aberrations were 
apparant. Eleven patients did not show cytogenetic abnormalities. In three patients 
the cytogenetic analysis could not be done. Among 25 adult patients (81%) the 
cytogenetic analysis revealed a t(9;22) in 6 patients, a translocation involving 11q23 
in one patient and diverse other cytogenetic aberrations in 11 patients. In 7 patients 
no cytogenetic aberrations were seen. In 5 patients no adequate analysis was done. 
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III vitro clIltlire alld growth factors 
DNA synthesis was assessed by uptake of 'H-thymidine ('H-TdR, specific activity 2 
Cilmmol;Amersham International, Amersham, UK) as described (11). In brief 
0.2xlO' cells were cultured in triplicate in 96 well dishes (Greiner, Alphen al d Rijn, 
The Netherlands) for 3 and 7 days in 100 ftl serum free culture medium (11). 
Eightteen hours before harvesting on nitrocellulose filters using a Titertek cell 
harvester (Flow Laboratories, Isrike, UK) 0.1 ~Ci 'H-TdR was added to the cultures. 
The amotrnt of desintegrations per minute (dpm) reflects DNA synthesis. 
Maxirnunl values of DNA synthesis on either day 4 or 7 'were used in the analysis. 
Human recombinant IL-7 (gift from Inmumex, Seattle, WA, USA) was added to the 
cultures at final concentrations of 100 U 1m!. Human IL-4 (Dr. S. Clark, Genetics 
Institute Cambridge, Massachusetts) was added to the cultures at a 1:5000 dilution 
of COS cell supernatant. 
Statistical allalysis 
IL-4 and IL'7 stimulation indices are expressed as ratios of DNA synthesis values 
of cultures with IL-4 or IL-7 relative to values of nonstimulated cultures 
(spontaneous proliferation). For purposes of tabulation and suvival curves the 
range of IL-4 and IL-7 ratio values were arbitrarily subdivided in 3 categories, 
labeled as low- (all values below the median), medium- (all values between the 
median and the third quartile) and high (all values above the third quartile) 
proliferative activities. Median for spontaneous proli-feration: 1883 desintegrations 
per minute (dpm). Median IL-4/spontaneous ratio: 0.8; median IL-7/spontaneous 
ratio: 1.4. Third quartile for IL-4/spontaneous ratio: 1.2; third quartile for 
IL-7/spontaneous ratio: 2.4. Mean spontaneous proliferation was 3909 dpm (lowest 
37 dpm, highest 40337 dpm). Mean IL-7 induced proliferation was 6371 dpm 
(lowest 147 dpm, highest 51362 dpm). Mean IL-4 induced proliferation was 3676 
dpm (lowest 70 dpm, highest 39275 dpm). Overall survival (OS) and event free 
survival (EFS) were the main endpoints. OS is defined as the time from diagnosis 
to death, whereas EFS is defined as the tinle from diagnosis to failure to attain clini-
cal remission (CR}(time set at to)' death in first CR (at time of death) or relapse after 
CR (at time of relapse). Correlations with probability to reach CR were not made, 
as all but 6 patients attained CR. 
Patients, alive in continuous CR, were censored at the time of last contact. Survival 
probabilities were calculated by the method of Kaplan and Meier (12). Cox re-
gression analysis ,vas applied to test for association between factors and OS or EFS 
(13). The log transforms of spontaneous proliferation values and the ratios of the 
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IL-4 and IL-7 induced proliferation values with respect to spontaneous 
proliferation were used in these analysis to test for trend (14). Correlations of the 
results of proliferation tests with as and EFS were studied with and without 
adjushnent for age in order to correlate pediatric and adult ALL separately. 
Table 1 
0-15 years ~315 years 
Nwnber of cases 43 3D 
Sex Male 26 21 
Female 17 9 
Diagnosis' null-ALL 2 4 
common-ALL 23 16 
pre-B-ALL 12 2 
T-ALL 6 8 
WEe s £50.000/ ml 24 18 
>50.000/ml 19 12 
median: 38.7 36.7 
range: 1.70 - 684 0.96 -386 
Cytogenetic t(9;22) 2 6 
Aberrations t(I;19) 2 0 
11q23 5 1 
other 20 11 
nomlal 11 7 
not determined/ 3 5 
no adequate 
analysis 
as defined in material and methods 
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6.3 Results 
Table 2 Clinical outcome of patients 
0-15 years ;?: 315 years 
Number of cases (n) 43 30 
Complete Response (%) 43 24 
(100%) (80%) 
Alh'e in continuous complete remission 29 8 
Rel.psed (n) 13 12 
Dead in complete remission 1 4 
Overall Survival'" 75%±8 21%± 10 
Event Free SurvivallJ 54%± 11 19%± 10 
°actuarial probability at 5 years ± SE 
Patiellt chamcteristics 
Patient characteristics for age groups 0-15 yrs and <:15 yrs of age are shown in 
table 1. In vitro proliferation in the nonstimulated cultures or stimulation of 
proliferation by IL-7 showed no significant differences between children and 
adults. Significant inhibition of DNA synthesis by IL-4 was noted in 66% of the 
cases (p=0.04). IL-4 induced inhibition of proliferation was not significantly diffe-
rent between children and adults (p=O.4). 
Clillical Olltcollle 
Table 1 summarizes the treatment results. All patients less than 15 yrs of age 
reached CR. In adults, CR was attained in 24 of 30 (80%) patients. Achtarial EFS of 
childhood patients at 5 years is 54% (±l1%SE). Five year EFS of adults is estimated 
at 19% (±10%SE). Five year as in children is 75% (±8%SE) and in adults 21% 
(±1O% SE). Young age appears a prominent favourable prognostic variable both for 
EFS and as (p<O.OOOOl), 
High versus low levels of spontaneous proliferation do not express impact on 
probability of as or EFS (figure 1, table 3). Inhibition of proliferation by IL-4 
correlates with a better as probability (p=O.03 Cox regression, corrected for 
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age)(figure 1, table 3). However, no correlation is apparant between IL-4 induced 
suppression of proliferation and EFS. Induction of proliferation by IL-7 did not 
correlate with as or EFS induced proliferation. WBC, percentage lymphoblasts in 
blood or bone marrow, or percentages of CD10 positive blasts did neither predict 
for as or EFS. 
Table 3 Overall survival (OS) and Event Free Survival (EFS) ± standard error (SE) in relation to 
spontaneous DNA synthesis in culture or in vitro proliferation in response to IL-7 or IL-4. In 60 cases, 
spontaneous-, IL-4 and IL-7 induced DNA synthesis was tested simultaneously. In 5 additional cases, 
spontaneous and lL-7 induced synthesis was tested simultaneously. In 8 cases spontaneous DNA 
synthesis only was tested. 
Nwnberof OS±SE P-valueil 
cases (%) 
low' 37 4S± 10 
Spontaneous 0.16 
proliferation 
high 36 58± 11 
low 32 69± 9 
IL-7 indllCed mediwn 17 48± 16 0.6 
proliferation 
high 16 51 + 14 
low 30 64 ± 12 
IL-4 induced 
suppression of medium 15 70 ± 13 0.03 
proliferation 
IL-7 induced high 15 44 ± 14 
adjusted for age, test for trend based on log transformed values 
low, medium and high as defined in materials and methods 
EFS±SE P-value'" 
(%) 
42± 10 
0.43 
40± 10 
49± 12 
26 ± 19 0.8 
45 + 14 
42 ± 13 
56± 14 0.16 
34± 14 
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Figure 1 Actuarial overall survival (OS) and event free survival (EFS) according to spontaneous 
(upper pannel) or JL-4 induced (lower pannel) in vitro proliferation. Curves were constructed by the 
Kaplan-Meier method. 
6.4 Discussion 
Hematopoietic growth factors like IL-7 and IL-4 Illay affect the level of DNA 
synthesis in normal and leukemic precursor Band T cells in culture (1-4). We 
analysed whether in vitro responsiveness of ALL cells to these growth factors 
correlates with clinical outcome. IL-4 suppressed the proliferative activity of ALL 
cells in vitro. Patients with a high level of impairment of DNA synthesis in cultures 
with IL-4 had better as. The significance of the latter relationship remains ques-
tionable since suppression of DNA synthesis by IL-4 did not predict for better EFS. 
Inhibition of proliferation of human lymphoid blast cells by IL-4 has been reported 
before (3,4,15). The small number of patients included in our analysis did not allow 
for a multivariate analysis of the IL-4 response and other prognostic factors. 
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However in l..mivariate analysis in this lirnited series of cases other generally 
accepted determinants as WBC did neither express prognostic value. Thus, we 
cannot rule out that the positive relationship or that the positive relationship 
between IL-4 response and as just appeared by chance. The potential difference in 
outcome predicted by the in vitro proliferative response to IL-4, would require 
further research. 
The responsiveness to IL-7 of ALL cells with different phenotypes is heterogeneous 
and does not follow the response pattem of normal BCP cells (2). According to the 
normal IL-7 response pattem, Pre-B-ALL rather than Null- and Common-ALL cells 
would have been expected to respond to IL-7. In this study we did not analyse the 
patients according to imnnmophenotype due to the limited number of patients. We 
did not find any relation between the IL-7 responsiveness and as or EFS. A 
possible relation between clinical outcome and the level of responsiveness to IL-7 
in distinct immunophenotype categories of ALL could not be addressed. 
Spontaneous in vitro proliferation of acute myeloid leukemia (AML) cells was 
shown to be a prognostic determinant (5). In ALL however, we do not find a 
statistically significant relation between the level of spontaneous proliferation and 
clinical outcome. This might be due to the limited number of patients studied, or 
indeed reflect a biological difference between AML and ALL. 
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Summary and discussion 
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7.1 Dissociation of IL-7 response and immunophenotype 
Based on immunophenotypic analysis acute lymphoblastic leukemia cells (ALL 
cells) are often considered to represent the neoplastic counterparts of normal B cells 
at distinct stages of development. Normal B cell development requires specific 
stimuli fronl the bone marrm.v rnicro envirOlIDlent as well as soluble growth 
factors. These requirements change with progressive differentiation of B cells. 
In Chapter 1 the different steps of normal B cell development are introduced. The 
genes coding for the Ig heavy and light chain genes are successively rearranged, 
defining different stages of B cell development. Eventually, proper rearrangement 
of both IgH ,oJ, chain genes results in the synthesis and expression of a functional B 
cell receptor, defining the stage of the immature B cell. IL-7 induces proliferation 
and differentiation in precursor B cells during distinct stages of maturation. 
Depending on the stage of development BCP cells respond to IL-7 either in synergy 
with other growth stimuli or as single growth factor. 
IL-7 binds to a specific membrane expressed IL-7R complex consisting of the 
IL-7Ra chain and the common y chain. The IL-7Ra chain belongs to the family of 
class I cytokine receptors based on structural honl010gies and does not have an 
intrinsic tyrosine kinase domain (1). Upon activation of these receptors three 
important signaling routes can be activated: the JAK/STAT pathway, the MAPK 
activation patlnvay or the PI3-kinase pathway. In addition protein tyrosine kinases 
like the Src kinase Fyn and Src like kinase Btk are activated. These signaling routes 
interact in several different ways with each other and have been fOlmd to play 
major roles in the control of proliferation and differentiation of hematopoietic cells 
(2,3). ALL cells somehow escape from the mechanisms that control proliferation 
and differentiation resulting in the accumulation of functionally defective cells in 
the bone marrow and peripheral blood. In Chapter 2 we analyse induction of 
proliferation in response to IL-7 in 72 samples of BCP-ALL and show that, in con-
trast to their normal cOlmterparts, BCP-ALL cells are highly heterogeneous in their 
response to IL-7. The response to IL-7 as single growth stimulus during normal 
murine B cell development is found to be dependent on the functional rearran-
gement and expression of the Ig heavy chain genes. We show that in BCP-ALL 
cells, the IL-7 response no longer depends on the rearrangement status of either Ig 
heavy or light chain genes. Proliferation in response to IL-7 is observed in cells that 
do not express Ig heavy chains, while absence of IL-7 induced proliferation in cells 
with functionally rearranged and expressed Ig heavy chain genes is seen as well. 
Moreover, we show that in contrast to primitive stages of nonnal B cell 
development, BCP-ALL cells lack synergistic responses to IL-7 and KL. This fits 
with the reported absence of c-kit expression in BCP-ALL cells (4). During differen-
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tiation of murine BCr cells the expression of c-kit is lost during transition from pre-
B-1 to pre-B-II cells (5). Absence of c-kit expression in BCr-ALL cells supports the 
idea that leukemic human BCr ALL cells represent functionally pre-B II cells. 
Three isofonns of the IL-7R a exist, including a nonsignaling soluble and a 
truncated, membrane bound form. We investigated the expression distribution of 
these splice variants and excluded overexpression of the nonfunctional isoforms of 
the IL-7Ra chain. Since the con1111On y chain is an essential part from the IL-7 
receptor we analyzed the expression of this chain and found it present in all cases. 
Therefore absence of the comn10n y cannot explain absence of IL-7 response. 
Based on in111mnophenotypic characteristics null- and conunon-ALL cells are 
arrested at the pre-B-I maturation stage (figure 2 chapter 1). In normal pre-B-I cells 
the IgH chain genes executed OJ" joining, but not yet VOJ" . Their respective IgL 
chain genes still have the germ line configuration. In null- and c-ALL however, 
VDJH rearrangernent as ,veIl as rearrangernents of the IgL chain are found. 
Therefore these cells belong genotypically to the pre-B-II cells. 
In murine pre-B-I cells proliferation is induced in response to IL-7 only in synergy 
with other growth stimuli, while pre-B II cells proliferate to IL-7 as single growth 
stimulus. The observation that a considerable number of null- and c-ALL cells 
respond to IL-7 as single growth stimulus, supports the hypothesis that these cells 
functionally represent pre-B-II cells and not pre-B-I cells. In that case proliferation, 
but not absence of proliferation in response to IL-7 as single growth stimulus is no 
longer aberrant, but implies dissociation of normally linked developmental events. 
Considering the generally low proliferative response to IL-7 of BCP-ALL cells, the 
highly heterogeneous response pattern to IL-7 in these cells and the absence of 
effect of IL-7 on cell survival in vitro, it seems tmlikely that IL-7 has a major 
influence in the expansion and accumulation of leukemic BCP cells. Nevertheless in 
a substantial number of cases the IL-7 response of Bcr-ALL cells is aberrant when 
compared to normal Bcr cells in comparable maturational stages. 
However, it must be noted that knowledge of the sequential IL-7 responses during 
normal B cell development is derived from murine models. It Calmot be excluded 
that human and murine B cell development are induced and controlled in different 
ways as is suggested by several observations. 
In murine in vivo models the function of IL-7 has been studied by either knocking 
out the IL-7 gene, neutralizing IL-7 by antibodies, disruption of the IL-7Ra or 
common y chain gene expression. III absence of a functional IL-7R complex or its 
ligand, both Band T cell development are seriously affected (6-10). 
III man no condition is known with complete absence of IL-7 or the IL-7Ra. 
However, in the X-linked SCIO syndrome, the COllunon y chain is non ftmctional 
because of a point mutation in the coding gene (11). This syndrome is characterized 
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by absent or diminished number of T cells and normal or even elevated number of 
B cells. B cells are not ftmctional due to absent T cells. The presence of normal or 
even elevated numbers of B cells is a distinct difference with common y chain 
lacking mice (10). It remains to be seen whether these B cells are capable of 
expression of the complete antigen receptor repertoire as B cell in non affected 
individuals. Recently Pribyl et al (12) showed IL-7 independent differentiation of 
human BCP cells in an in vitro system. It seems therefore that although IL-7 in B 
cell development is an important factor for both proliferation and differentiation of 
BCP cells, its absence in man can be compensated by other regulatory factors. 
7.2 Involvement of CD20 and CD40 in the proliferation of 
BCP-ALL cells 
CD20 expression follows CD19 expression early in B cell ontogeny. It is expressed 
exclusively on B cell lineage cells. Expression of CD20 declines from the stage of 
mature B cells. Stimulation with IL-7 upregulates the expression of CD20 (13). The 
function of CD20 is largely unknown. Since no natural ligand (if existing at all) is 
known for CD20, antibodies against CD20 are used to investigate its function. 
Following anti CD20 antibody induced activation, tyrosine and serine kinase 
activity is observed, suggesting association with tyrosine kinases, since C020 does 
not have an intrinsic tyrosine kinase domain (14, 15). Indeed association with the 
Src family tyrosine kinases p56/53Iyn, p56lck and p59fyn has been reported (16). 
CD20 plays a direct role in transmembrane Ca" conductance (17) although the 
precise mechanism renlains to be elucidated. It is tmclear whether C020 forms a 
Ca" by multimerisation of CD20 molecules or that other transmembrane molecules 
are involved as well (18). Following activation, CD20 is phosphorylated on 
multiple serine/threonine residues. In vitro kinases assays revealed that CD20 is a 
substrate for ubiquitous serine/threonine kinases like PKC, CKII and CaM-K11 
(19-22). Each kInase is thought to phosphorylate CD20 on specific residues 
resulting in different functional consequences, like PKC induced phosphorylation 
of CD20 abrogating the Ca" flux (23). Depending on the phosphorylation on 
threonine and serine residues, three forms of CD20 can be fOlmd with either 33, 35 
or 37 kDa. No ligand is known for CD20 and the possibility remains that CD20 
does not have an extra cellular ligand, but acts as a Ca ++ channel in response to 
cellular activation. Indeed, upon cell activation through the Ig receptor or through 
CD40 activation, CD20 is activated as well resulting in progression of cell cycle. 
Activation of CD20 via IF5 induces cell cycle progression from GO to Gl but not to 
S phase (24-26). In Chapter 3 we investigated the effects of activation of B cell 
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surface antigen CD20. CD20 was activated via binding to the mouse antibody IF5. 
In 18 out of 58 cases of BCP-ALL of all immunophenotype, CD20 activation 
resulted in a significant increase in DNA synthesis. No synergy ·was observed with 
other growth factors. Responses or absence of responses were not related to 
immunophenotype or expression of CD20. Cell-cycle progression from Gl into S 
phase depends on decreased [CaH], levels(27, 28). Progression to S phase in res-
ponse to CD20 activation, suggests failure to inhibit drop in [CaH], in leukemic 
cells. The stahlS of phosphorylation of CD20 in leukemic cells is unknown. Possibly 
constitutively active phosphorylation on specific serine/threonine residues renlains 
CD20 in the activated state or is PKC induced phosphorylation inhibited, resulting 
in failure to end the Ca" flux. Progression to S phase in leukemic cells however, 
may reflect preactivation of proliferative signaling pathways, replacing the extra 
growth stinmlus (like IL-7), needed in normal BCPs to proliferate in response to 
CD20 activation. 
In Chapter 3 we further present the results of CD40 activation in BCP-ALL cells. In 
mature B cells activation of CD40 induces cell cycle progression into S phase. Only 
in synergy with other growth stimuli like IL-4 and CD20 activation (29-32) 
proliferation is induced. In BCP-ALL cells activation of CD40 alone induces DNA 
synthesis in 10 out of 44 cases. Simultaneous stimulation with other growth factors 
like IL-3, IL-4 or IL-7 in the majority of cases was not synergistic. 
CD40 expression on BCP cells starts early in B cell ontogeny i.e. at the pro-B cell 
stage (33). Expression is also seen in malignant BCP cells at various stages of 
mahlration (33, 34). Activation of CD40 in normal human BCP cells induces prolife-
ration only in conjtmction with other growth stinmli like IL-3, IL-7 or IL-I0 (35). 
The natural ligand for CD40 is expressed on activated T cells (36), but the ftmction 
of CD40 in BCP remains to be elucidated. Following CD40 activation a number of 
serine/threonine kinases are activated in addition to activation of CD40 associated 
tyrosine kinases. In response to CD40 activation, phosphorylation of CD20 was 
observed in a PKC dependent manner (20), suggesting cross talk between these 
two molecules. However in our experiments in acute lymphoblastic leukenlia cells 
the mitogenic responses to activation of CD20 or CD40 appeared to be 
independent, suggesting interruption of connecting signaling routes, thereby losing 
an inlportant control mechanism over proliferation through these signaling 
molecules. In table 1 the proliferative responses to various growth stimuli in 
hUlnan, murine and leukelnic ncp cells are sUlnmarized. 
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Table 1 Effects of different growth stimuli on human, murine and leukemic BCP cells 
Stimulus 
lL-7 
JL-3 
IGF 1(;"),/<) 
C020 activation 
C040 activation 
Normal BCr cens 
Proliferation of pre-B-II cells. 
Proliferation of pro-B cells in 
synergy with FLt3-ligand. 
Proliferation of Pre-B cells in 
addition to JL-7 response. 
Proliferation in pro-B cells. 
Synergistic proliferation of 
pre-B-I-cells with IL-7. 
Proliferation of pro-B and 
Pre-B-I cells. 
Synergy with IL-7 in Pre-B-Cells. 
Proliferation of pro-B cells and possibly 
pre-B-I cells. 
Cell cycle transition from Go- G[ in 
C020 expressing B cells. 
Progression to S phase in synergy 
with other growth stimuli like C040 
activation. 
Leukemic Bcr cells 
Proliferation of some but not all 
Pre- B-II cells. 
Idem 
No effect either as Single growth 
stimulus or in synergy with IL-7. 
No effect either as single growth 
stimulus or in synergy with IL-7. 
No effect either as single growth 
stimulus or in synergy with JL-7. 
Cell cycle transition from G,,-G1- S 
independent from additional growth 
stimuli in a significant number of 
BCP ALL samples. 
Cell cycle transition from Go-Go S Cell cycle transition from Gl - G2 - S in 
phase if additional stimuli like IL-3, IL-7 absence of additional stimuli. No 
or 1L-10 are present. synergy with IL-4 or IL-7. 
7.3 The JAKISTAT pathway in leukemia 
In Chapter 4 results are presented of the investigation of signaling events following 
activation of the IL-7 receptor in human BCP-ALL cells as compared with signaling 
through the IL-7Ra chain in a murine cell model. 
Upon stimulation of BCP-ALL cells with IL-7 the activation of Jakl, but not Jak2 or 
Jak3 was observed. 1n addition gel retardation assays revealed the formation STAT 
complexes identified by supershifts with anti-STAT antibodies to be STATl and 
STATS complexes. Activation of STAT complexes was found in patients with and 
without a proliferative response to IL-7, suggests other signaling events are needed 
for proliferative signaling. To study the contribution of the IL-7Ra chain in the 
signaling events of the IL-7R complex, we constructed a chimeric receptor protein 
consisting of the extracellular domain of the G-CSF receptor and transmembrane 
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plus intracellular domain of the IL-7 receptor. Activation of this chimeric receptor 
by hG-CSF results in dimer complex formation and activation of signaling 
molecules resulting in G-CSF induced proliferation. Upon transfection and 
activation of the chuneric receptor in the I1l0USe pro B cell line BaF3, activation of 
Jakl, but not Jak2 or Jak3 was seen. In addition STATl and STAT5 containing 
complexes were formed, as well as some STAT3 containing complexes. 
Interestingly, a similarly constructed chimeric receptor with the transmembrane 
part derived from the h-G-CSF receptor did not induce proliferation upon 
transfection despite clear expression of the receptor. This suggests an important 
role for the IL-7Ra chaul transnlenlbrane dmnain in proliferative signaling. 
Possibly the transmembrane dOlllaUl plays a role in the recruitrnent of rnernbrane 
bound signaling molecules like for instance the myristylated Src like molecule Fyn. 
It is ho\vever also possible that due to confonnational changes, ditnerization is 
hampered resulting in lack of proliferative signaling. Future research is needed to 
elucicate this nlatter. 
It is generally thought that for proliferative signaling through the IL-7R complex 
the presence of the common y chain is necessary (37). The absence of Jak3 activation 
supports the hypothesis that the common y chain in BaF3 cells does not associate 
with the chimeric receptor. Furtherrnore, binding of the conunon y chain occurs 
through binding to the ligand and the common y chain does not have affinity for 
hG-CSF, the ligand of the chimeric receptor. Moreover, expression of the common y 
chain in BaF3 cells is undetectably low (38). Data presented here show therefore 
that the IL-7Ra chain in absence of the common y chain can elicit a full mitogenic 
signal. 
Recently the JAK-STAT pathway was suggested to be involved in oncogenic 
transformation. Mutation of the Drosophila JAK analogue Hop-tum, rendering 
constitntive activation, caused leukemia like hematopoietic defects (39, 40) and in 
acute myeloid and lymphoid leukemic cells STAT molecules were found to be con-
stitutively activated (41). Inhibition of constitntively activated JAK by tyrphostin, 
by interference with the kinase domain of JAK, inhibited leukemic cell proliferati-
on, suggesting a possible role for the JAK/STAT pathway in leukemia (42). 
However, STATs have been implicated in inhibition of proliferation as well. A 
mutant form of the Epo receptor wlable to activate STAT5, exhibited increased 
proliferation induction upon stimulation (43). Also STAT1 and STAT3 activation 
have been reported to induce proliferation inhibition (44-46). We did not find 
constitutive activation of the JAK/STAT pathway in ALL cells. Most likely 
additional signaling events are involved in regulation of proliferation and in 
leukemogenesis. The fWlction and effect of activation of STAT molecules in 
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response to activation of the IL-7R complex in normal and leukemic BCP cells 
needs further investigation. 
7.4 Signaling through the IL-7R a chain 
In chapter 5 we investigated through the construction of chimeric receptors the 
signaling properties of the IL-7Ra chain when introduced in BaF3 cells. Various 
constructs were composed of the extracellular domain of the human G-CSF recep-
ter and the complete or tnmcated intracellular domains of the IL-7Ra chain. IL-7Ra 
chain mutants missing the carboxy terminus of the IL-7R were tmable to transduce 
proliferative signals. The transn1eInbrane domain was either derived fron) the G-
CSF-R or the IL-7R. Results showed abrogation of mitogenic signaling when the 
transmembrane domain was derived from the G-CSF-R. The possible role of the 
transmembrane domain of cytokine receptors in n1itogenic signaling is discussed. 
Induction of proliferation was fotmd to coincide with activated JAKI. Chin1eras 
able to induce proliferation, activated ERKI/ERK2 molecules without activation of 
the Grb2/Shc complex. This in1plicates an alternative activation of the p21 Ras 
pathway. Co-precipitation of IRS-2 with the PI3 kinase subunit p8S in activated 
cells bearing the proliferation inducing chin1eras, suggests involvement of these 
IRS-2 and PI3 kinase in the p21 Ras pathway. Finally, activation of STAT5 was seen 
independent of JAK activation. Alternative n1echanisms to activate STAT 
molecules are discussed. 
7.5 Clinical relevance of cytokine responses 
In Chapter 6 we have investigated the clinical significance of in vitro proliferation 
of ALL cells in response to IL-4 and IL-7. IL-4 was found to inhibit in vitro 
proliferation in most cases tested. Responses to IL-7 were highly heterogeneous as 
described in chapter 2. Inhibition with IL-4 correlated with a better overall 
survival, but due to the linlited number of patients and the hetereogeneous 
character of ALL, no multivariate analysis could be performed. IL-7 and 
proliferation in absence of HGFs did not show relation with clinical outcome. The 
study confirmed age as an important clinical prognostic parameter. Conclusions 
are difficult to draw, since confidence intervals were large and statistical difference 
difficult to achieve. These data reflect the heterogeneity of ALL and suggest that 
responses to IL-7 are not of clinical importance in ALL. 
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Concluding remarks 
Cytokines are involved in control and regulation of hematopoiesis. The cellular 
response to cytokines depends on cell type and stage of maturation. In acute 
lymphoblastic leukemia the regulated process of proliferation and differentiation is 
disturbed and the normal link between inummophenotype and genotype lost. The 
response to cytokines may help to functionally define leukemia cells. In this thesis 
we analysed the response of ALL cells to IL-7 and found the response pattern to be 
highly heterogeneous in all immuno-phenotypic subclasses. We have not been able 
to identify a general mechanism of dysregulation of the IL-7 response. Develop-
ment of new in vitro culture teclmiques is necessary to study the role of IL-7 during 
the sequential events in B cell development. Differences in responses to IL-7 
stimulation cannot be explained by lack of expression of a ftmctional IL-7R. This 
urges to further investigate the downstream processes following IL-7 stimulation in 
normal and leukemic BCP cells. 
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Samenvatting in Nederlands 
Hematopoiese of bloedcelvorming is het proces waarbij zich vanuit een pluripoten-
te stamcel de verschillende soorten bloedcellen ontwikkelen. De bloedcellen 
bestaan uit rode en witte bloedcellen en bloedplaatjes. Witte bloedcellen kwmen 
worden onderscheiden in granulocyten, Iymfocyten en macrofagen en spelen een 
belangrijke rol bij de afweer tegen lichaamsvreemde stoffen (antigenen). Lymfocy-
ten klumen worden onderscheiden in T en B lymphocyten, die beiden nauw 
samenwerken tijdens een afweerreactie. Door verbruik van lymfocyten dient eell 
voortdurende aanmaak van nieuwe cellen plaats te vinden. Dit gebeurt in het been-
merg waar een specifiek milieu zorgt voor de juiste groei en ontwikkelingscondi-
ties. 
Gedurende het traject van primitieve stamcel tot volledig uigerijpte (gedifferen-
tieerde) lymfocyt, wordt een aantal ontwikkelingsstappen doorlopen. Deze worden 
besproken in hoofdstuk 1. 
Rijpe B cellen brengen op de celmembraan een llmmnoglobuline (Ig) tot expressie, 
waara an antigenen zeer specifieke kunnen binden. Aangezien er zeer veel verschil-
lende sOOlten antigenen bestaan, nloeten er evenveel verschillende Ig's bestaan. 
Hiertoe wordt tijdens de ontwikkeling van de B cel voorlopercellen (de B cell 
precursor cells~ BCP) een serie DNA herschikkingen uitgevoerd van de verschil-
lende onderdelen van het de genen die coderen voor het uiteindelijke Ig. 
Verschillende stadia van genherschikking definieren discrete ontwikkelings-stadia 
van de B cel voorlopercellen: pro-B, pre-B-I en pre-B-II. Niet aileen uitrijping maar 
ook vermenigvuldiging (proliferatie) van de verschillende ontwikkelingsstadia is 
van groot belang. 
Hematopoietische groeifactoren (HGF's) zijn hormoonachtige stoffen die zowel de 
proliferatie als differentia tie processen sturen. HGF's oefenen hun werking op 
cellen uit door middel van activering van zogenaamde receptor structuren die in 
de celmembraan verankerd zijn. In dit proefschrift is de rol onderzocht van 
verschillende HGF's in proliferatie en differentiatie van nonnale en leukemische B 
cel voorlopercellen. Voor een van deze HGF's, intel'leukine 7 (IL-7), is onderzocht 
welke intracellulaire processen plaatsvinden na binding van IL-7 en daarmee 
activatie van zijn eigen receptor op de celwand van de BCP. 
Acute lymfatische leukemie (ALL) is een kwaadaardige ziekte, waarbij de controle 
over proliferatie en differentia tie van lymfocyten verloren is. Elk type ALL kent 
ophopIng van B of T voorlopercellen in een bepaald stadium van de ontwikkeling. 
Deze ophoping van onrijpe cellen verstoort de normale aanmaak van bloedcellen, 
met als gevolg bloedarmoede, stollingsstoornissen, en sterk verminderde afweer. 
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De respons op IL-7, maar ook op andere groeifactoren, wordt bepaald door het 
ontwikkelingsstadium waarin de cel verkeert. 
In hoofdstuk 2 is onderzocht of de leukemische voorloper B cellen (BCP-ALL 
cellen) op IL-7 reageren zoals normale voorloper B cellen in een vergelijkbaar 
ontwikkelingsstadium zouden doen. 
Dit bleek niet het geval te zijn. De respons op IL-7 van BCP-ALL cellen viel niet 
samen met het ontwikkelings stadium van de cel. Onderzocht is of de receptor 
voor IL-7 compleet tot expressie komt, hetgeen het geval blijkt te zijn. Geconelu-
deerd kan worden dat BCP-ALL cellen zich ten aanzien van groeifaetor respons 
anders gedragen dan normale BCP cellen en derhalve niet beschouwd hmnen 
worden als vertegenwool'digers van deze nonnale ontwikkelingsstadia. 
In Hoofdstuk 3 onderzochten wij de respons van BCP-ALL cellen op activatie van 
CD20 en CD40. CD20 en CD40 zijn eiwitten die tot expressie komen op de celwand 
van BCP cellen. Van CD20 is de funetie niet bekend. De vorm van het eiwit doet 
vermoeden dat het een receptor is, maar een ligand is niet bekend. Activatie van 
CD20 in normale BCP cellen leidt tot progressie in de cel cyelus van fase GO tot Gl. 
Deze fasen gaan vDoraf aan de fasen waarin de eel zich vernlenigv·uldigt. Activatie 
van CD20 wordt gezien in samenhang Inet activatie van de eel door signalen van 
buitenaf. 
In dit onderzoek hebben we CD20 kunstmatig geaetiveerd met een anti CD20 
antilichaam. Gevonden werd dat BCP-ALL cellen in respons op CD20 aetivatie niet 
slechts van GO fase van de celcyclus in de Gl fase overgingen, nlaar verder gingen 
tot de 5 fase, die direct met proliferatie samenhangt. Er werd geen versterking van 
de respons waargenomen door gelijktijdige stimulatie met andere stimuli, 
waaronder IL-7. 
CD40 is de receptor voor het zogenaamde CD40-ligand (CD40-L). Activatie van 
CD40 kan plaatsvinden door binding met dit ligand, maar ook door binding van 
anti CD40 antilichamen. CD40-L wordt tot expressie gebracht door T-cellen en 
stroma cellen in de thymus en beenmerg. De CD40jCD40-L interactie is belangrijk 
voor proliferatie en mogelijk ook voor differentiatie. In normale BCP cellen leidt 
CD40 activatie tot cel cyelus progressie van Gl tot 5 fase aileen als tegelijkertijd 
stimulatie plaatsvindt met 
IL-3, IL-7, IL-10 of CD20-aetivatie. In BCP-ALL cellen werd proliferatie door aileen 
CD40 activatie gezien in een aantal gevallen en was in geen enkel geval versterking 
van respons gezien door toevoeging van andere groeifactoren. Geconcludeerd 
wordt dat BCP-ALL cellen zich ten aanzien van de respons op CD20- of CD40-
aetivatie anders gedragen dan normale BCP cellen. 
In hoofdstuk 4 en 5 wordt de lnanier waarop intracellulaire processen worden 
geaetiveerd door IL-7 nader onderzocht. IL-7 bindt aan een specifiek IL-7R 
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complex bestaande uit een IL-7Ra keten en een common y keten. Na binding van 
IL-7 voIgt een cascade van activatie van signaaImoleculen uiteindelijk resulterend 
in verandering van expressie van genen. 
In hoofdstuk 4 wordt beschreven dat in BCP-ALL cellen de JAK/STAT signaalweg 
wordt geactiveerd in respons op IL-7. STATl en STAT5 complexen worden 
gevormd zowel in BCP-ALL cellen die prolifereren na IL-7 stimulatie als in BCP-
ALL cellen die dat niet doen. Om te onderzoeken welke signaalwegen door de 
IL-7Ra keten onafhankelijk van de y, keten worden geactiveerd, construeerden wij 
een kunstrnatige receptor uit het extra cellulaire deel van de G-CSF-R en het 
intracellulaire deel van de IL-7Ra keten (chimere receptor). Identieke forma tie van 
STAT complexen werden gevonden, mailr bovendien forma tie van STAT 
complexen waarin STA T3 is betrokken. 
In hoofdstuk 5 beschrijven we forma tie van STAT5 complexen door een chimere 
receptor waarin het transmembraan gedeelte van de IL-7Ra keten is vervangen. 
Activatie van deze receptor leidt niet tot proliferatie. Blijkbaar vervult het 
transmembraan gedeelte een nog onbekende functie in het doorgeven van proli-
feratieve signalen. In afwezigheid van het transmembraan gedeelte van de IL-7R 
vindt geen JAKI activatie plaats, evenmin als activatie van enkele andere belang-
rijke signaal moleculen (IRS-2, Syp, MAPK). Daarentegen worden weI STAT5 
complexen gevonden. De rol van het transmembraan gedeelte wordt bediscussi-
eerd. Daamaast wordt geconcludeerd dat STAT5 activatie kan plaatsvinden 
onafhankelijk van JAK activatie. 
In hoofdstuk 6 hebben wij gekeken naar de mogelijke klinische relevantie van 
groeifactor gelnduceerde groei in vitro van leukemische B- en T- voorlopercellen bij 
een groep van 73 kinderen en volwassen patienten met ALL. Wij vonden geen aan-
wijzing dat er een verband bestaat tussen de in vitro groei karakteristieken en het 
klinisch beloop. 
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